1
|
Martin E, Winter S, Garcin C, Tanita K, Hoshino A, Lenoir C, Fournier B, Migaud M, Boutboul D, Simonin M, Fernandes A, Bastard P, Le Voyer T, Roupie AL, Ben Ahmed Y, Leruez-Ville M, Burgard M, Rao G, Ma CS, Masson C, Soudais C, Picard C, Bustamante J, Tangye SG, Cheikh N, Seppänen M, Puel A, Daly M, Casanova JL, Neven B, Fischer A, Latour S. Role of IL-27 in Epstein-Barr virus infection revealed by IL-27RA deficiency. Nature 2024; 628:620-629. [PMID: 38509369 DOI: 10.1038/s41586-024-07213-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Accepted: 02/20/2024] [Indexed: 03/22/2024]
Abstract
Epstein-Barr virus (EBV) infection can engender severe B cell lymphoproliferative diseases1,2. The primary infection is often asymptomatic or causes infectious mononucleosis (IM), a self-limiting lymphoproliferative disorder3. Selective vulnerability to EBV has been reported in association with inherited mutations impairing T cell immunity to EBV4. Here we report biallelic loss-of-function variants in IL27RA that underlie an acute and severe primary EBV infection with a nevertheless favourable outcome requiring a minimal treatment. One mutant allele (rs201107107) was enriched in the Finnish population (minor allele frequency = 0.0068) and carried a high risk of severe infectious mononucleosis when homozygous. IL27RA encodes the IL-27 receptor alpha subunit5,6. In the absence of IL-27RA, phosphorylation of STAT1 and STAT3 by IL-27 is abolished in T cells. In in vitro studies, IL-27 exerts a synergistic effect on T-cell-receptor-dependent T cell proliferation7 that is deficient in cells from the patients, leading to impaired expansion of potent anti-EBV effector cytotoxic CD8+ T cells. IL-27 is produced by EBV-infected B lymphocytes and an IL-27RA-IL-27 autocrine loop is required for the maintenance of EBV-transformed B cells. This potentially explains the eventual favourable outcome of the EBV-induced viral disease in patients with IL-27RA deficiency. Furthermore, we identified neutralizing anti-IL-27 autoantibodies in most individuals who developed sporadic infectious mononucleosis and chronic EBV infection. These results demonstrate the critical role of IL-27RA-IL-27 in immunity to EBV, but also the hijacking of this defence by EBV to promote the expansion of infected transformed B cells.
Collapse
Affiliation(s)
- Emmanuel Martin
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Sarah Winter
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
- Université Paris Cité, Paris, France
| | - Cécile Garcin
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
- Université Paris Cité, Paris, France
| | - Kay Tanita
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Akihiro Hoshino
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Christelle Lenoir
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Benjamin Fournier
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
- Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Mélanie Migaud
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France
| | - David Boutboul
- Université Paris Cité, Paris, France
- Department of Hematology, Cochin Hospital, AP-HP, Paris, France
| | - Mathieu Simonin
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Alicia Fernandes
- Plateforme Vecteurs Viraux et Transfert de Gènes, Institut Necker Enfants Malades, Necker-Enfants Malades Hospital, APHP, Paris, France
| | - Paul Bastard
- Université Paris Cité, Paris, France
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Tom Le Voyer
- Université Paris Cité, Paris, France
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Anne-Laure Roupie
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
- Université Paris Cité, Paris, France
| | - Yassine Ben Ahmed
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Marianne Leruez-Ville
- Service de Bactériologie, Virologie, Parasitologie et Hygiène, Necker-Enfants Malades Hospital, Paris, France
| | - Marianne Burgard
- Service de Bactériologie, Virologie, Parasitologie et Hygiène, Necker-Enfants Malades Hospital, Paris, France
| | - Geetha Rao
- Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia
| | - Cindy S Ma
- Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia
- St Vincent's Clinical School, Faculty of Medicine and Health, Sydney, New South Wales, Australia
| | - Cécile Masson
- Plateforme de Bioinformatique, INSERM UMR1163, Université de Paris, Imagine Institute, Paris, France
| | - Claire Soudais
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
- Université Paris Cité, Paris, France
| | - Capucine Picard
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
- Université Paris Cité, Paris, France
- Study Center for Primary Immunodeficiencies, Necker-Enfants Malades Hospital, APHP, Paris, France
| | - Jacinta Bustamante
- Université Paris Cité, Paris, France
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France
- Study Center for Primary Immunodeficiencies, Necker-Enfants Malades Hospital, APHP, Paris, France
- St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
| | - Stuart G Tangye
- Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia
- St Vincent's Clinical School, Faculty of Medicine and Health, Sydney, New South Wales, Australia
| | - Nathalie Cheikh
- Hôpital Jean Minjoz, Centre Hospitalo-Universitaire de Besançon, Besançon, France
| | - Mikko Seppänen
- Pediatric Research Center and Rare Disease Center, New Children's Hospital, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland
| | - Anne Puel
- Université Paris Cité, Paris, France
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France
- St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
| | - Mark Daly
- Institut for Molecular Medecine Finland, University of Helsinki, Helsinki, Finland
| | - Jean-Laurent Casanova
- Université Paris Cité, Paris, France
- Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France
- St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
- Howard Hughes Medical Institute, New York, NY, USA
| | - Bénédicte Neven
- Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Alain Fischer
- Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
- Collège de France, Paris, France
- Imagine Institute, INSERM UMR 1163, Paris, France
| | - Sylvain Latour
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
- Université Paris Cité, Paris, France.
| |
Collapse
|
2
|
Soudais C, Schaus R, Bachelet C, Minet N, Mouasni S, Garcin C, Souza CL, David P, Cousu C, Asnagli H, Parker A, Palmquist-Gomes P, Sepulveda FE, Storck S, Meilhac SM, Fischer A, Martin E, Latour S. Inactivation of cytidine triphosphate synthase 1 prevents fatal auto-immunity in mice. Nat Commun 2024; 15:1982. [PMID: 38438357 PMCID: PMC10912214 DOI: 10.1038/s41467-024-45805-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Accepted: 01/25/2024] [Indexed: 03/06/2024] Open
Abstract
De novo synthesis of the pyrimidine, cytidine triphosphate (CTP), is crucial for DNA/RNA metabolism and depends on the CTP synthetases, CTPS1 and -2. Partial CTPS1 deficiency in humans has previously been shown to lead to immunodeficiency, with impaired expansion of T and B cells. Here, we examine the effects of conditional and inducible inactivation of Ctps1 and/or Ctps2 on mouse embryonic development and immunity. We report that deletion of Ctps1, but not Ctps2, is embryonic-lethal. Tissue and cells with high proliferation and renewal rates, such as intestinal epithelium, erythroid and thymic lineages, activated B and T lymphocytes, and memory T cells strongly rely on CTPS1 for their maintenance and growth. However, both CTPS1 and CTPS2 are required for T cell proliferation following TCR stimulation. Deletion of Ctps1 in T cells or treatment with a CTPS1 inhibitor rescued Foxp3-deficient mice from fatal systemic autoimmunity and reduced the severity of experimental autoimmune encephalomyelitis. These findings support that CTPS1 may represent a target for immune suppression.
Collapse
Affiliation(s)
- Claire Soudais
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Institut Imagine, Paris, France.
- Université de Paris Cité, Paris, France.
| | - Romane Schaus
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Institut Imagine, Paris, France
| | - Camille Bachelet
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Institut Imagine, Paris, France
- Université de Paris Cité, Paris, France
| | - Norbert Minet
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Institut Imagine, Paris, France
- Université de Paris Cité, Paris, France
| | - Sara Mouasni
- Laboratory of Molecular Basis of Altered Immune Homeostasis Inserm UMR 1163, Institut Imagine, Paris, France
| | - Cécile Garcin
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Institut Imagine, Paris, France
- Université de Paris Cité, Paris, France
| | - Caique Lopes Souza
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Institut Imagine, Paris, France
- Université de Paris Cité, Paris, France
| | - Pierre David
- Transgenesis Platform, Laboratoire d'Expérimentation Animale et Transgenèse (LEAT), Institut Imagine-Structure Fédérative de Recherche Necker INSERM US24/CNRS, UMS3633, Paris, France
| | - Clara Cousu
- Université Paris Cité, CNRS UMR 8253, INSERM U1151, Institut Necker Enfants Malades, F-75015, Paris, France
| | - Hélène Asnagli
- Step-Pharma, Technoparc du Pays-de-Gex, Saint-Genis-Pouilly, France
| | - Andrew Parker
- Step-Pharma, Technoparc du Pays-de-Gex, Saint-Genis-Pouilly, France
| | - Paul Palmquist-Gomes
- Université de Paris Cité, Paris, France
- Imagine - Institut Pasteur, Unit of Heart Morphogenesis, INSERM UMR1163, F-75015, Paris, France
| | - Fernando E Sepulveda
- Laboratory of Molecular Basis of Altered Immune Homeostasis Inserm UMR 1163, Institut Imagine, Paris, France
| | - Sébastien Storck
- Université Paris Cité, CNRS UMR 8253, INSERM U1151, Institut Necker Enfants Malades, F-75015, Paris, France
| | - Sigolène M Meilhac
- Université de Paris Cité, Paris, France
- Imagine - Institut Pasteur, Unit of Heart Morphogenesis, INSERM UMR1163, F-75015, Paris, France
| | - Alain Fischer
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Institut Imagine, Paris, France
- Collège de France, Paris, France
| | - Emmanuel Martin
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Institut Imagine, Paris, France
| | - Sylvain Latour
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Institut Imagine, Paris, France.
- Université de Paris Cité, Paris, France.
| |
Collapse
|
3
|
Minet N, Boschat AC, Lane R, Laughton D, Beer P, Asnagli H, Soudais C, Bourne T, Fischer A, Martin E, Latour S. Differential roles of CTP synthetases CTPS1 and CTPS2 in cell proliferation. Life Sci Alliance 2023; 6:e202302066. [PMID: 37348953 PMCID: PMC10288033 DOI: 10.26508/lsa.202302066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 06/06/2023] [Accepted: 06/07/2023] [Indexed: 06/24/2023] Open
Abstract
The CTP nucleotide is a key precursor of nucleic acids metabolism essential for DNA replication. De novo CTP production relies on CTP synthetases 1 and 2 (CTPS1 and CTPS2) that catalyze the conversion of UTP into CTP. CTP synthetase activity is high in proliferating cells including cancer cells; however, the respective roles of CTPS1 and CTPS2 in cell proliferation are not known. By inactivation of CTPS1 and/or CTPS2 and complementation experiments, we showed that both CTPS1 and CTPS2 are differentially required for cell proliferation. CTPS1 was more efficient in promoting proliferation than CTPS2, in association with a higher intrinsic enzymatic activity that was more resistant to inhibition by 3-deaza-uridine, an UTP analog. The contribution of CTPS2 to cell proliferation was modest when CTPS1 was expressed but essential in absence of CTPS1. Public databases analysis of more than 1,000 inactivated cancer cell lines for CTPS1 or CTPS2 confirmed that cell growth is highly dependent of CTPS1 but less or not of CTPS2. Therefore, our results demonstrate that CTPS1 is the main contributor to cell proliferation.
Collapse
Affiliation(s)
- Norbert Minet
- Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Inserm UMR 1163, Imagine Institute, Paris, France
- Université de Paris, Paris, France
| | - Anne-Claire Boschat
- Université de Paris, Paris, France
- Plateforme Spectrométrie de masse, Institut Imagine, Paris, France
- Laboratoire de Biochimie Métabolomique et Protéomique, Hôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | | | | | | | | | - Claire Soudais
- Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Inserm UMR 1163, Imagine Institute, Paris, France
- Université de Paris, Paris, France
| | - Tim Bourne
- Step-Pharma, Saint-Genis-Pouilly, France
| | - Alain Fischer
- Collège de France, Paris, France
- Imagine Institute, Paris, France
| | - Emmanuel Martin
- Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Inserm UMR 1163, Imagine Institute, Paris, France
- Université de Paris, Paris, France
| | - Sylvain Latour
- Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Inserm UMR 1163, Imagine Institute, Paris, France
- Université de Paris, Paris, France
| |
Collapse
|
4
|
Fournier B, Hoshino A, Bruneau J, Bachelet C, Fusaro M, Klifa R, Lévy R, Lenoir C, Soudais C, Picard C, Blanche S, Castelle M, Moshous D, Molina T, Defachelles AS, Neven B, Latour S. Inherited TNFSF9 deficiency causes broad Epstein-Barr virus infection with EBV+ smooth muscle tumors. J Exp Med 2022; 219:213262. [PMID: 35657354 PMCID: PMC9170382 DOI: 10.1084/jem.20211682] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 03/16/2022] [Accepted: 04/25/2022] [Indexed: 01/07/2023] Open
Abstract
Epstein-Barr virus (EBV) can infect smooth muscle cells causing smooth muscle tumors (SMTs) or leiomyoma. Here, we report a patient with a heterozygous 22q11.2 deletion/DiGeorge syndrome who developed a unique, broad, and lethal susceptibility to EBV characterized by EBV-infected T and B cells and disseminated EBV+SMT. The patient also harbored a homozygous missense mutation (p.V140G) in TNFSF9 coding for CD137L/4-1BBL, the ligand of the T cell co-stimulatory molecule CD137/4-1BB, whose deficiency predisposes to EBV infection. We show that wild-type CD137L was up-regulated on activated monocytes and dendritic cells, EBV-infected B cells, and SMT. The CD137LV140G mutant was weakly expressed on patient cells or when ectopically expressed in HEK and P815 cells. Importantly, patient EBV-infected B cells failed to trigger the expansion of EBV-specific T cells, resulting in decreased T cell effector responses. T cell expansion was recovered when CD137L expression was restored on B cells. Therefore, these results highlight the critical role of the CD137-CD137L pathway in anti-EBV immunity, in particular in the control of EBV+SMT.
Collapse
Affiliation(s)
- Benjamin Fournier
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut national de la santé et de la recherche médicale UMR 1163, Paris, France,Paris Cité University, Imagine Institute, Paris, France,Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Akihiro Hoshino
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut national de la santé et de la recherche médicale UMR 1163, Paris, France
| | - Julie Bruneau
- Department of Pathology, Necker-Enfants Malades Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Camille Bachelet
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut national de la santé et de la recherche médicale UMR 1163, Paris, France,Paris Cité University, Imagine Institute, Paris, France
| | - Mathieu Fusaro
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut national de la santé et de la recherche médicale UMR 1163, Paris, France,Paris Cité University, Imagine Institute, Paris, France,Study Center for Primary Immunodeficiencies, Necker-Enfants Malades Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Roman Klifa
- Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Romain Lévy
- Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Christelle Lenoir
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut national de la santé et de la recherche médicale UMR 1163, Paris, France
| | - Claire Soudais
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut national de la santé et de la recherche médicale UMR 1163, Paris, France,Paris Cité University, Imagine Institute, Paris, France
| | - Capucine Picard
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut national de la santé et de la recherche médicale UMR 1163, Paris, France,Paris Cité University, Imagine Institute, Paris, France,Study Center for Primary Immunodeficiencies, Necker-Enfants Malades Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Stéphane Blanche
- Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Martin Castelle
- Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Despina Moshous
- Paris Cité University, Imagine Institute, Paris, France,Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Thierry Molina
- Department of Pathology, Necker-Enfants Malades Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
| | | | - Bénédicte Neven
- Paris Cité University, Imagine Institute, Paris, France,Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
| | - Sylvain Latour
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut national de la santé et de la recherche médicale UMR 1163, Paris, France,Paris Cité University, Imagine Institute, Paris, France,Correspondence to Sylvain Latour:
| |
Collapse
|
5
|
Babin L, Darchen A, Robert E, Aid Z, Borry R, Soudais C, Piganeau M, De Cian A, Giovannangeli C, Bawa O, Rigaud C, Scoazec JY, Couronné L, Veleanu L, Cieslak A, Asnafi V, Sibon D, Lamant L, Meggetto F, Mercher T, Brunet E. De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells. Mol Cancer 2022; 21:65. [PMID: 35246138 PMCID: PMC8895835 DOI: 10.1186/s12943-022-01520-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Accepted: 01/21/2022] [Indexed: 11/12/2022] Open
Abstract
Background Anaplastic large cell lymphoma positive for ALK (ALK+ ALCL) is a rare type of non-Hodgkin lymphoma. This lymphoma is caused by chromosomal translocations involving the anaplastic lymphoma kinase gene (ALK). In this study, we aimed to identify mechanisms of transformation and therapeutic targets by generating a model of ALK+ ALCL lymphomagenesis ab initio with the specific NPM-ALK fusion. Methods We performed CRISPR/Cas9-mediated genome editing of the NPM-ALK chromosomal translocation in primary human activated T lymphocytes. Results Both CD4+ and CD8+ NPM-ALK-edited T lymphocytes showed rapid and reproducible competitive advantage in culture and led to in vivo disease development with nodal and extra-nodal features. Murine tumors displayed the phenotypic diversity observed in ALK+ ALCL patients, including CD4+ and CD8+ lymphomas. Assessment of transcriptome data from models and patients revealed global activation of the WNT signaling pathway, including both canonical and non-canonical pathways, during ALK+ ALCL lymphomagenesis. Specifically, we found that the WNT signaling cell surface receptor ROR2 represented a robust and genuine marker of all ALK+ ALCL patient tumor samples. Conclusions In this study, ab initio modeling of the ALK+ ALCL chromosomal translocation in mature T lymphocytes enabled the identification of new therapeutic targets. As ROR2 targeting approaches for other cancers are under development (including lung and ovarian tumors), our findings suggest that ALK+ ALCL cases with resistance to current therapies may also benefit from ROR2 targeting strategies. Supplementary Information The online version contains supplementary material available at 10.1186/s12943-022-01520-0.
Collapse
Affiliation(s)
- Loélia Babin
- Laboratory of the « Genome Dynamics in the Immune System », Équipe Labellisée La Ligue Contre Le Cancer, Université de Paris, Université Paris Saclay, INSERM UMR 1163, Institut Imagine, Paris, France
| | - Alice Darchen
- Laboratory of the « Genome Dynamics in the Immune System », Équipe Labellisée La Ligue Contre Le Cancer, Université de Paris, Université Paris Saclay, INSERM UMR 1163, Institut Imagine, Paris, France
| | - Elie Robert
- Programme PEDIAC, Equipe labellisée Ligue Contre le Cancer, OPALE Carnot Institute, Université Paris Saclay, INSERM Unité U1170, Gustave Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94805, Villejuif, France
| | - Zakia Aid
- Programme PEDIAC, Equipe labellisée Ligue Contre le Cancer, OPALE Carnot Institute, Université Paris Saclay, INSERM Unité U1170, Gustave Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94805, Villejuif, France
| | - Rosalie Borry
- Laboratory of the « Genome Dynamics in the Immune System », Équipe Labellisée La Ligue Contre Le Cancer, Université de Paris, Université Paris Saclay, INSERM UMR 1163, Institut Imagine, Paris, France
| | - Claire Soudais
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Université de Paris, INSERM UMR1163, Institut Imagine, Paris, France
| | - Marion Piganeau
- INSERM U1154, CNRS UMR 7196, Sorbonne Universités, Museum National d'Histoire Naturelle, 43 rue Cuvier, F-75231, Paris, France
| | - Anne De Cian
- INSERM U1154, CNRS UMR 7196, Sorbonne Universités, Museum National d'Histoire Naturelle, 43 rue Cuvier, F-75231, Paris, France
| | - Carine Giovannangeli
- INSERM U1154, CNRS UMR 7196, Sorbonne Universités, Museum National d'Histoire Naturelle, 43 rue Cuvier, F-75231, Paris, France
| | - Olivia Bawa
- PETRA platform, AMMICa, University Paris Saclay, CNRS-UMS 3655 Inserm US23, Gustave Roussy, 94805, Villejuif, France
| | - Charlotte Rigaud
- Department of Pediatric and Adolescent Oncology, Gustave Roussy, 94805, Villejuif, France
| | - Jean-Yves Scoazec
- Department of Pathology, AMMICa CNRS UMS3655 Inserm US23 Université Paris Saclay, Gustave Roussy, 94805, Villejuif, France
| | - Lucile Couronné
- Laboratory of Onco Hematology, Hôpital Necker - Enfants Malades, Assistance Publique Hôpitaux de Paris (APHP); Laboratory of Normal and pathological lymphoid differentiation, University of Paris, INSERM U1151, INEM Institute, Paris, France
| | - Layla Veleanu
- Université de Paris, Institut Necker-Enfants Malades (INEM), INSERM U1151, and Laboratory of Onco-Hematology, AP-HP Hôpital Necker Enfants-Malades, Paris, France
| | - Agata Cieslak
- Université de Paris, Institut Necker-Enfants Malades (INEM), INSERM U1151, and Laboratory of Onco-Hematology, AP-HP Hôpital Necker Enfants-Malades, Paris, France
| | - Vahid Asnafi
- Université de Paris, Institut Necker-Enfants Malades (INEM), INSERM U1151, and Laboratory of Onco-Hematology, AP-HP Hôpital Necker Enfants-Malades, Paris, France
| | - David Sibon
- Université de Paris, Institut Necker-Enfants Malades (INEM), INSERM U1151, and Laboratory of Onco-Hematology, AP-HP Hôpital Necker Enfants-Malades, Paris, France
| | - Laurence Lamant
- Université Toulouse III-Paul Sabatier, Laboratoire d'Excellence Toulouse Cancer-TOUCAN, Équipe Labellisée La Ligue Contre Le Cancer, CNRS UMR5071, Inserm, UMR1037, CRCT, F-31000, Toulouse, France
| | - Fabienne Meggetto
- Université Toulouse III-Paul Sabatier, Laboratoire d'Excellence Toulouse Cancer-TOUCAN, Équipe Labellisée La Ligue Contre Le Cancer, CNRS UMR5071, Inserm, UMR1037, CRCT, F-31000, Toulouse, France
| | - Thomas Mercher
- Programme PEDIAC, Equipe labellisée Ligue Contre le Cancer, OPALE Carnot Institute, Université Paris Saclay, INSERM Unité U1170, Gustave Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94805, Villejuif, France.
| | - Erika Brunet
- Laboratory of the « Genome Dynamics in the Immune System », Équipe Labellisée La Ligue Contre Le Cancer, Université de Paris, Université Paris Saclay, INSERM UMR 1163, Institut Imagine, Paris, France.
| |
Collapse
|
6
|
Martin E, Minet N, Boschat AC, Sanquer S, Sobrino S, Lenoir C, de Villartay JP, Leite-de-Moraes M, Picard C, Soudais C, Bourne T, Hambleton S, Hughes SM, Wynn RF, Briggs TA, Patel S, Lawrence MG, Fischer A, Arkwright PD, Latour S. Impaired lymphocyte function and differentiation in CTPS1-deficient patients result from a hypomorphic homozygous mutation. JCI Insight 2020; 5:133880. [PMID: 32161190 PMCID: PMC7141395 DOI: 10.1172/jci.insight.133880] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Accepted: 01/29/2020] [Indexed: 01/01/2023] Open
Abstract
Cytidine triphosphate (CTP) synthetase 1 (CTPS1) deficiency is caused by a unique homozygous frameshift splice mutation (c.1692-1G>C, p.T566Dfs26X). CTPS1-deficient patients display severe bacterial and viral infections. CTPS1 is responsible for CTP nucleotide de novo production involved in DNA/RNA synthesis. Herein, we characterized in depth lymphocyte defects associated with CTPS1 deficiency. Immune phenotyping performed in 7 patients showed absence or low numbers of mucosal-associated T cells, invariant NKT cells, memory B cells, and NK cells, whereas other subsets were normal. Proliferation and IL-2 secretion by T cells in response to TCR activation were markedly decreased in all patients, while other T cell effector functions were preserved. The CTPS1T566Dfs26X mutant protein was found to be hypomorphic, resulting in 80%-90% reduction of protein expression and CTPS activity in cells of patients. Inactivation of CTPS1 in a T cell leukemia fully abolished cell proliferation. Expression of CTPS1T566Dfs26X failed to restore proliferation of CTPS1-deficient leukemia cells to normal, except when forcing its expression to a level comparable to that of WT CTPS1. This indicates that CTPS1T566Dfs26X retained normal CTPS activity, and thus the loss of function of CTPS1T566Dfs26X is completely attributable to protein instability. This study supports that CTPS1 represents an attractive therapeutic target to selectively inhibit pathological T cell proliferation, including lymphoma.
Collapse
Affiliation(s)
- Emmanuel Martin
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Imagine Institute, Paris, France
| | - Norbert Minet
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Imagine Institute, Paris, France
- University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France
| | - Anne-Claire Boschat
- University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France
- Plateforme spectrométrie de masse, Imagine Institute, Paris, France
- Laboratoire de Biochimie Métabolomique et Protéomique, Hôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Sylvia Sanquer
- Laboratoire de Biochimie Métabolomique et Protéomique, Hôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Steicy Sobrino
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Imagine Institute, Paris, France
- University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France
| | - Christelle Lenoir
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Imagine Institute, Paris, France
| | - Jean Pierre de Villartay
- University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France
- Laboratory of Genome Dynamics in the Immune System, Inserm UMR 1163, Imagine Institute, Paris, France
| | - Maria Leite-de-Moraes
- Inserm UMR S1151 CNRS UMR 8253, Institut Necker Enfants Malades (INEM), Paris, France
| | - Capucine Picard
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Imagine Institute, Paris, France
- University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France
- Centre d’Etude des Déficits Immunitaires, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
- Department of Pediatric Immunology, Hematology and Rheumatology, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
| | - Claire Soudais
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Imagine Institute, Paris, France
- University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France
| | | | - Sophie Hambleton
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
| | | | | | - Tracy A. Briggs
- Division of Evolution and Genomic Sciences, and
- Lydia Becker Institute of Immunology & Inflammation, University of Manchester, Manchester, United Kingdom
| | | | - Smita Patel
- John Radcliffe Hospital, Oxford, United Kingdom
| | - Monica G. Lawrence
- Division of Asthma, Allergy & Immunology, University of Virginia, Charlottesville, Virginia, USA
| | - Alain Fischer
- University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France
- Department of Pediatric Immunology, Hematology and Rheumatology, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
- Collège de France, Paris, France
- Inserm UMR 1163, Paris, France
| | | | - Sylvain Latour
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, Imagine Institute, Paris, France
- University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France
| |
Collapse
|
7
|
Izawa K, Martin E, Soudais C, Bruneau J, Boutboul D, Rodriguez R, Lenoir C, Hislop AD, Besson C, Touzot F, Picard C, Callebaut I, de Villartay JP, Moshous D, Fischer A, Latour S. Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection. J Exp Med 2016; 214:73-89. [PMID: 28011863 PMCID: PMC5206497 DOI: 10.1084/jem.20160784] [Citation(s) in RCA: 103] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2016] [Revised: 08/13/2016] [Accepted: 10/25/2016] [Indexed: 12/13/2022] Open
Abstract
Izawa et al. identify the first patient with CD70 deficiency suffering from recurrent EBV-induced B cell proliferations including Hodgkin’s lymphoma. Expression of CD70 on B cells is necessary to induce proliferation of EBV-specific T cells. Epstein-Barr virus (EBV) infection in humans is a major trigger of malignant and nonmalignant B cell proliferations. CD27 is a co-stimulatory molecule of T cells, and inherited CD27 deficiency is characterized by high susceptibility to EBV infection, though the underlying pathological mechanisms have not yet been identified. In this study, we report a patient suffering from recurrent EBV-induced B cell proliferations including Hodgkin’s lymphoma because of a deficiency in CD70, the ligand of CD27. We show that EBV-specific T lymphocytes did not expand properly when stimulated with CD70-deficient EBV-infected B cells, whereas expression of CD70 in B cells restored expansion, indicating that CD70 on B cells but not on T cells is required for efficient proliferation of T cells. CD70 was found to be up-regulated on B cells when activated and during EBV infection. The proliferation of T cells triggered by CD70-expressing B cells was dependent on CD27 and CD3 on T cells. Importantly, CD27-deficient T cells failed to proliferate when stimulated with CD70-expressing B cells. Thus, the CD70–CD27 pathway appears to be a crucial component of EBV-specific T cell immunity and more generally for the immune surveillance of B cells and may be a target for immunotherapy of B cell malignancies.
Collapse
Affiliation(s)
- Kazushi Izawa
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut National de la Santé et de la Recherche Médicale UMR 1163, 75015 Paris, France
| | - Emmanuel Martin
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut National de la Santé et de la Recherche Médicale UMR 1163, 75015 Paris, France
| | - Claire Soudais
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut National de la Santé et de la Recherche Médicale UMR 1163, 75015 Paris, France.,University Paris Descartes Sorbonne Paris Cité, Imagine Institut, 75015 Paris, France
| | - Julie Bruneau
- University Paris Descartes Sorbonne Paris Cité, Imagine Institut, 75015 Paris, France.,Department of Pathology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
| | - David Boutboul
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut National de la Santé et de la Recherche Médicale UMR 1163, 75015 Paris, France
| | - Rémy Rodriguez
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut National de la Santé et de la Recherche Médicale UMR 1163, 75015 Paris, France.,University Paris Descartes Sorbonne Paris Cité, Imagine Institut, 75015 Paris, France
| | - Christelle Lenoir
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut National de la Santé et de la Recherche Médicale UMR 1163, 75015 Paris, France
| | - Andrew D Hislop
- School of Cancer Sciences, University of Birmingham, Birmingham B15 2TT, England, UK
| | - Caroline Besson
- Department of Biological Hematology and Immunology, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, 94270 Le Kremlin-Bicêtre, France
| | - Fabien Touzot
- University Paris Descartes Sorbonne Paris Cité, Imagine Institut, 75015 Paris, France.,Department of Biotherapy, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
| | - Capucine Picard
- Laboratory of Human Genetics of Infectious Diseases, Institut National de la Santé et de la Recherche Médicale UMR 1163, 75015 Paris, France.,University Paris Descartes Sorbonne Paris Cité, Imagine Institut, 75015 Paris, France.,Centre d'Etude des Déficits Immunitaires, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France.,Department of Pediatric Immunology, Hematology, and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
| | - Isabelle Callebaut
- Centre National de la Recherche Scientifique UMR 7590, Sorbonne Universities, University Pierre et Marie Curie-Paris 6-MNHN-IRD-IUC, 75005 Paris, France
| | - Jean-Pierre de Villartay
- Laboratory of Dynamic of Genome and Immune System, Institut National de la Santé et de la Recherche Médicale UMR 1163, 75015 Paris, France.,University Paris Descartes Sorbonne Paris Cité, Imagine Institut, 75015 Paris, France
| | - Despina Moshous
- Laboratory of Dynamic of Genome and Immune System, Institut National de la Santé et de la Recherche Médicale UMR 1163, 75015 Paris, France.,University Paris Descartes Sorbonne Paris Cité, Imagine Institut, 75015 Paris, France.,Department of Pediatric Immunology, Hematology, and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
| | - Alain Fischer
- University Paris Descartes Sorbonne Paris Cité, Imagine Institut, 75015 Paris, France.,Department of Pediatric Immunology, Hematology, and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France.,Collège de France, 75005 Paris, France.,Institut National de la Santé et de la Recherche Médicale UMR 1163, 75015 Paris, France
| | - Sylvain Latour
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut National de la Santé et de la Recherche Médicale UMR 1163, 75015 Paris, France .,University Paris Descartes Sorbonne Paris Cité, Imagine Institut, 75015 Paris, France
| |
Collapse
|
8
|
Cui Y, Franciszkiewicz K, Mburu YK, Mondot S, Le Bourhis L, Premel V, Martin E, Kachaner A, Duban L, Ingersoll MA, Rabot S, Jaubert J, De Villartay JP, Soudais C, Lantz O. Mucosal-associated invariant T cell-rich congenic mouse strain allows functional evaluation. J Clin Invest 2015; 125:4171-85. [PMID: 26524590 DOI: 10.1172/jci82424] [Citation(s) in RCA: 124] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Accepted: 09/03/2015] [Indexed: 01/11/2023] Open
Abstract
Mucosal-associated invariant T cells (MAITs) have potent antimicrobial activity and are abundant in humans (5%-10% in blood). Despite strong evolutionary conservation of the invariant TCR-α chain and restricting molecule MR1, this population is rare in laboratory mouse strains (≈0.1% in lymphoid organs), and lack of an appropriate mouse model has hampered the study of MAIT biology. Herein, we show that MAITs are 20 times more frequent in clean wild-derived inbred CAST/EiJ mice than in C57BL/6J mice. Increased MAIT frequency was linked to one CAST genetic trait that mapped to the TCR-α locus and led to higher usage of the distal Vα segments, including Vα19. We generated a MAIThi congenic strain that was then crossed to a transgenic Rorcgt-GFP reporter strain. Using this tool, we characterized polyclonal mouse MAITs as memory (CD44+) CD4-CD8lo/neg T cells with tissue-homing properties (CCR6+CCR7-). Similar to human MAITs, mouse MAITs expressed the cytokine receptors IL-7R, IL-18Rα, and IL-12Rβ and the transcription factors promyelocytic leukemia zinc finger (PLZF) and RAR-related orphan receptor γ (RORγt). Mouse MAITs produced Th1/2/17 cytokines upon TCR stimulation and recognized a bacterial compound in an MR1-dependent manner. During experimental urinary tract infection, MAITs migrated to the bladder and decreased bacterial load. Our study demonstrates that the MAIThi congenic strain allows phenotypic and functional characterization of naturally occurring mouse MAITs in health and disease.
Collapse
MESH Headings
- Animals
- Chemotaxis, Leukocyte
- Crosses, Genetic
- Disease Models, Animal
- Female
- Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor
- Germ-Free Life
- Histocompatibility Antigens Class I/immunology
- Humans
- Immunologic Memory
- Kruppel-Like Transcription Factors/analysis
- Lymphocyte Activation
- Lymphocyte Count
- Lymphoid Tissue/cytology
- Lymphokines/metabolism
- Mice
- Mice, Congenic/genetics
- Mice, Congenic/immunology
- Mice, Congenic/microbiology
- Mice, Inbred C57BL
- Mice, Knockout
- Mice, Transgenic
- Microbiota
- Minor Histocompatibility Antigens
- Natural Killer T-Cells/immunology
- Natural Killer T-Cells/metabolism
- Nuclear Receptor Subfamily 1, Group F, Member 3/analysis
- Phenotype
- Polymorphism, Single Nucleotide
- Promyelocytic Leukemia Zinc Finger Protein
- Radiation Chimera
- Receptors, Antigen, T-Cell, alpha-beta/genetics
- Receptors, Cytokine/analysis
- Urinary Tract Infections/immunology
- Urinary Tract Infections/microbiology
Collapse
|
9
|
Okada S, Markle JG, Deenick EK, Mele F, Averbuch D, Lagos M, Alzahrani M, Al-Muhsen S, Halwani R, Ma CS, Wong N, Soudais C, Henderson LA, Marzouqa H, Shamma J, Gonzalez M, Martinez-Barricarte R, Okada C, Avery DT, Latorre D, Deswarte C, Jabot-Hanin F, Torrado E, Fountain J, Belkadi A, Itan Y, Boisson B, Migaud M, Arlehamn CSL, Sette A, Breton S, McCluskey J, Rossjohn J, de Villartay JP, Moshous D, Hambleton S, Latour S, Arkwright PD, Picard C, Lantz O, Engelhard D, Kobayashi M, Abel L, Cooper AM, Notarangelo LD, Boisson-Dupuis S, Puel A, Sallusto F, Bustamante J, Tangye SG, Casanova JL. IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science 2015; 349:606-613. [PMID: 26160376 DOI: 10.1126/science.aaa4282] [Citation(s) in RCA: 309] [Impact Index Per Article: 34.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2014] [Accepted: 06/29/2015] [Indexed: 12/16/2022]
Abstract
Human inborn errors of immunity mediated by the cytokines interleukin-17A and interleukin-17F (IL-17A/F) underlie mucocutaneous candidiasis, whereas inborn errors of interferon-γ (IFN-γ) immunity underlie mycobacterial disease. We report the discovery of bi-allelic RORC loss-of-function mutations in seven individuals from three kindreds of different ethnic origins with both candidiasis and mycobacteriosis. The lack of functional RORγ and RORγT isoforms resulted in the absence of IL-17A/F-producing T cells in these individuals, probably accounting for their chronic candidiasis. Unexpectedly, leukocytes from RORγ- and RORγT-deficient individuals also displayed an impaired IFN-γ response to Mycobacterium. This principally reflected profoundly defective IFN-γ production by circulating γδ T cells and CD4(+)CCR6(+)CXCR3(+) αβ T cells. In humans, both mucocutaneous immunity to Candida and systemic immunity to Mycobacterium require RORγ, RORγT, or both.
Collapse
Affiliation(s)
- Satoshi Okada
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065, USA.,Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan
| | - Janet G Markle
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065, USA
| | - Elissa K Deenick
- Immunology Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.,St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia
| | - Federico Mele
- Institute for Research in Biomedicine, University of Italian Switzerland, Bellinzona, Switzerland
| | - Dina Averbuch
- Department of Pediatrics, Hadassah University Hospital, Jerusalem, Israel
| | - Macarena Lagos
- Department of Immunology, School of Medicine, Universidad de Valparaíso, Santiago, Chile.,Department of Pediatrics, Padre Hurtado Hospital and Clinica Alemana, Santiago, Chile
| | - Mohammed Alzahrani
- Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Saleh Al-Muhsen
- Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.,Department of Pediatrics, Prince Naif Center for Immunology Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Rabih Halwani
- Department of Pediatrics, Prince Naif Center for Immunology Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Cindy S Ma
- Immunology Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.,St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia
| | - Natalie Wong
- Immunology Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.,St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia
| | | | - Lauren A Henderson
- Division of Immunology, Boston Children's Hospital, Boston, MA 02115, USA
| | - Hiyam Marzouqa
- Caritas Baby Hospital, Post Office Box 11535, Jerusalem, Israel
| | - Jamal Shamma
- Caritas Baby Hospital, Post Office Box 11535, Jerusalem, Israel
| | - Marcela Gonzalez
- Department of Immunology, School of Medicine, Universidad de Valparaíso, Santiago, Chile.,Department of Pediatrics, Hadassah University Hospital, Jerusalem, Israel
| | - Rubén Martinez-Barricarte
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065, USA
| | - Chizuru Okada
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065, USA
| | - Danielle T Avery
- Immunology Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.,St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia
| | - Daniela Latorre
- Institute for Research in Biomedicine, University of Italian Switzerland, Bellinzona, Switzerland
| | - Caroline Deswarte
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Paris, France.,Paris Descartes University, Imagine Institute, Paris, France
| | - Fabienne Jabot-Hanin
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Paris, France.,Paris Descartes University, Imagine Institute, Paris, France
| | | | | | - Aziz Belkadi
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Paris, France.,Paris Descartes University, Imagine Institute, Paris, France
| | - Yuval Itan
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065, USA
| | - Bertrand Boisson
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065, USA
| | - Mélanie Migaud
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Paris, France.,Paris Descartes University, Imagine Institute, Paris, France
| | | | - Alessandro Sette
- La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
| | - Sylvain Breton
- Department of Radiology, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Hospital for Sick Children, Paris, France
| | - James McCluskey
- Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia
| | - Jamie Rossjohn
- Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia.,Australian Research Council Centre of Excellence for Advanced Molecular Imaging, Monash University, Clayton, Victoria, Australia.,Institute of Infection and Immunity, Cardiff University, School of Medicine, Heath Park, Cardiff CF14 4XN, UK
| | - Jean-Pierre de Villartay
- Laboratoire Dynamique du Génome et Système Immunitaire, INSERM UMR 1163, Université Paris Descartes-Sorbonne Paris Cité, Imagine Institute, Paris, France
| | - Despina Moshous
- Laboratoire Dynamique du Génome et Système Immunitaire, INSERM UMR 1163, Université Paris Descartes-Sorbonne Paris Cité, Imagine Institute, Paris, France.,Pediatric Hematology-Immunology Unit, AP-HP, Necker Hospital for Sick Children, Paris, France
| | - Sophie Hambleton
- Institute of Cellular Medicine, Newcastle University and Great North Children's Hospital, Newcastle upon Tyne NE4 6BE, UK
| | - Sylvain Latour
- Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, INSERM UMR 1163, Université Paris Descartes-Sorbonne Paris Cité, Imagine Institute, Paris, France
| | - Peter D Arkwright
- Department of Paediatric Allergy Immunology, University of Manchester, Royal Manchester Children's Hospital, Manchester, UK
| | - Capucine Picard
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065, USA.,Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Paris, France.,Paris Descartes University, Imagine Institute, Paris, France.,Pediatric Hematology-Immunology Unit, AP-HP, Necker Hospital for Sick Children, Paris, France.,Center for the Study of Primary Immunodeficiencies, AP-HP, Necker Hospital for Sick Children, Paris, France
| | | | - Dan Engelhard
- Department of Pediatrics, Hadassah University Hospital, Jerusalem, Israel
| | - Masao Kobayashi
- Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan
| | - Laurent Abel
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065, USA.,Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Paris, France.,Paris Descartes University, Imagine Institute, Paris, France
| | | | - Luigi D Notarangelo
- Division of Immunology, Boston Children's Hospital, Boston, MA 02115, USA.,Manton Center for Orphan Disease Research, Children's Hospital, Boston, MA 02115, USA
| | - Stéphanie Boisson-Dupuis
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065, USA.,Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Paris, France.,Paris Descartes University, Imagine Institute, Paris, France
| | - Anne Puel
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065, USA.,Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Paris, France.,Paris Descartes University, Imagine Institute, Paris, France
| | - Federica Sallusto
- Institute for Research in Biomedicine, University of Italian Switzerland, Bellinzona, Switzerland.,Center of Medical Immunology, Institute for Research in Biomedicine, University of Italian Switzerland, Bellinzona, Switzerland
| | - Jacinta Bustamante
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065, USA.,Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Paris, France.,Paris Descartes University, Imagine Institute, Paris, France.,Center for the Study of Primary Immunodeficiencies, AP-HP, Necker Hospital for Sick Children, Paris, France
| | - Stuart G Tangye
- Immunology Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.,St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia
| | - Jean-Laurent Casanova
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065, USA.,Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Paris, France.,Paris Descartes University, Imagine Institute, Paris, France.,Pediatric Hematology-Immunology Unit, AP-HP, Necker Hospital for Sick Children, Paris, France.,Howard Hughes Medical Institute, New York, NY 10065, USA
| |
Collapse
|
10
|
Soudais C, Samassa F, Sarkis M, Le Bourhis L, Bessoles S, Blanot D, Hervé M, Schmidt F, Mengin-Lecreulx D, Lantz O. In Vitro and In Vivo Analysis of the Gram-Negative Bacteria-Derived Riboflavin Precursor Derivatives Activating Mouse MAIT Cells. J Immunol 2015; 194:4641-9. [PMID: 25870247 DOI: 10.4049/jimmunol.1403224] [Citation(s) in RCA: 83] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/24/2014] [Accepted: 03/12/2015] [Indexed: 12/11/2022]
Abstract
Mucosal-associated invariant T (MAIT) cells recognize microbial compounds presented by the MHC-related 1 (MR1) protein. Although riboflavin precursor derivatives from Gram-positive bacteria have been characterized, some level of ligand heterogeneity has been suggested through the analysis of the MAIT cell TCR repertoire in humans and differential reactivity of human MAIT cell clones according to the bacteria. In this study, using Gram-negative bacteria mutated for the riboflavin biosynthetic pathway, we show a strict correlation between the ability to synthesize the 5-amino-ribityl-uracil riboflavin precursor and to activate polyclonal and quasi-monoclonal mouse MAIT cells. To our knowledge, we show for the first time that the semipurified bacterial fraction and the synthetic ligand activate murine MAIT cells in vitro and in vivo. We describe new MR1 ligands that do not activate MAIT cells but compete with bacterial and synthetic compounds activating MAIT cells, providing the capacity to modulate MAIT cell activation. Through competition experiments, we show that the most active synthetic MAIT cell ligand displays the same functional avidity for MR1 as does the microbial compound. Altogether, these results show that most, if not all, MAIT cell ligands found in Escherichia coli are related to the riboflavin biosynthetic pathway and display very limited heterogeneity.
Collapse
Affiliation(s)
| | | | - Manal Sarkis
- INSERM U932, Paris 75005, France; Département de Chimie, Institut Curie, Unité Mixte de Recherche 176, Paris 75005, France
| | | | | | - Didier Blanot
- Laboratoire des Enveloppes Bactériennes et Antibiotiques, Institut de Biochimie et Biophysique Moléculaire et Cellulaire, Unité Mixte de Recherche 8619, Centre National de la Recherche Scientifique, Université Paris-Sud, 91405 Orsay, France
| | - Mireille Hervé
- Laboratoire des Enveloppes Bactériennes et Antibiotiques, Institut de Biochimie et Biophysique Moléculaire et Cellulaire, Unité Mixte de Recherche 8619, Centre National de la Recherche Scientifique, Université Paris-Sud, 91405 Orsay, France
| | - Frédéric Schmidt
- Département de Chimie, Institut Curie, Unité Mixte de Recherche 176, Paris 75005, France
| | - Dominique Mengin-Lecreulx
- Laboratoire des Enveloppes Bactériennes et Antibiotiques, Institut de Biochimie et Biophysique Moléculaire et Cellulaire, Unité Mixte de Recherche 8619, Centre National de la Recherche Scientifique, Université Paris-Sud, 91405 Orsay, France
| | - Olivier Lantz
- INSERM U932, Paris 75005, France; Département de Biologie des Tumeurs, Institut Curie, Paris 75005, France; and Centre d'Investigation Clinique, CICBT507 IGR/Curie, Paris 75005, France
| |
Collapse
|
11
|
Magalhaes I, Pingris K, Poitou C, Bessoles S, Venteclef N, Kiaf B, Beaudoin L, Da Silva J, Allatif O, Rossjohn J, Kjer-Nielsen L, McCluskey J, Ledoux S, Genser L, Torcivia A, Soudais C, Lantz O, Boitard C, Aron-Wisnewsky J, Larger E, Clément K, Lehuen A. Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients. J Clin Invest 2015; 125:1752-62. [PMID: 25751065 DOI: 10.1172/jci78941] [Citation(s) in RCA: 228] [Impact Index Per Article: 25.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2014] [Accepted: 01/15/2015] [Indexed: 12/11/2022] Open
Abstract
Obesity and type 2 diabetes (T2D) are associated with low-grade inflammation, activation of immune cells, and alterations of the gut microbiota. Mucosal-associated invariant T (MAIT) cells, which are innate-like T cells that recognize bacterial ligands, are present in blood and enriched in mucosal and inflamed tissues. Here, we analyzed MAIT cells in the blood and adipose tissues of patients with T2D and/or severe obesity. We determined that circulating MAIT cell frequency was dramatically decreased in both patient groups, and this population was even undetectable in some obese patients. Moreover, in both patient groups, circulating MAIT cells displayed an activated phenotype that was associated with elevated Th1 and Th17 cytokine production. In obese patients, MAIT cells were more abundant in adipose tissue than in the blood and exhibited a striking IL-17 profile. Bariatric surgery in obese patients not only improved their metabolic parameters but also increased circulating MAIT cell frequency at 3 months after surgery. Similarly, cytokine production by blood MAIT cells was strongly decreased after surgery. This study reveals profound MAIT cell abnormalities in patients harboring metabolic disorders, suggesting their potential role in these pathologies.
Collapse
|
12
|
Seach N, Guerri L, Le Bourhis L, Mburu Y, Cui Y, Bessoles S, Soudais C, Lantz O. Double-positive thymocytes select mucosal-associated invariant T cells. J Immunol 2013; 191:6002-9. [PMID: 24244014 DOI: 10.4049/jimmunol.1301212] [Citation(s) in RCA: 100] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
NKT and mucosal-associated invariant T (MAIT) cells express semi-invariant TCR and restriction by nonclassical MHC class Ib molecules. Despite common features, the respective development of NKT and MAIT subsets is distinct. NKTs proliferate extensively and acquire effector properties prior to thymic export. MAIT cells exit the thymus as naive cells and acquire an effector/memory phenotype in a process requiring both commensal flora and B cells. During thymic development, NKTs are selected by CD1d-expressing cortical thymocytes; however, the hematopoietic cell type responsible for MAIT cell selection remains unresolved. Using reaggregated thymic organ culture and bone marrow chimeras, we demonstrate that positive selection of mouse iVα19 transgenic and Vβ6 transgenic MAIT cell progenitors requires MHC-related 1-expressing CD4(+)CD8(+) double positive thymocytes, whereas thymic B cells, macrophages, and dendritic cell subsets are dispensable. Preincubation of double positive thymocytes with exogenous bacterial ligand increases MHC-related 1 surface expression and enhances mature MAIT cell activation in the in vitro cocultures. The revelation of a common cell type for the selection of both NKT and MAIT subsets raises questions about the mechanisms underlying acquisition of their specific features.
Collapse
|
13
|
Le Bourhis L, Dusseaux M, Bohineust A, Bessoles S, Martin E, Premel V, Coré M, Sleurs D, Serriari NE, Treiner E, Hivroz C, Sansonetti P, Gougeon ML, Soudais C, Lantz O. MAIT cells detect and efficiently lyse bacterially-infected epithelial cells. PLoS Pathog 2013; 9:e1003681. [PMID: 24130485 PMCID: PMC3795036 DOI: 10.1371/journal.ppat.1003681] [Citation(s) in RCA: 279] [Impact Index Per Article: 25.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2013] [Accepted: 08/21/2013] [Indexed: 12/11/2022] Open
Abstract
Mucosal associated invariant T cells (MAIT) are innate T lymphocytes that detect a large variety of bacteria and yeasts. This recognition depends on the detection of microbial compounds presented by the evolutionarily conserved major-histocompatibility-complex (MHC) class I molecule, MR1. Here we show that MAIT cells display cytotoxic activity towards MR1 overexpressing non-hematopoietic cells cocultured with bacteria. The NK receptor, CD161, highly expressed by MAIT cells, modulated the cytokine but not the cytotoxic response triggered by bacteria infected cells. MAIT cells are also activated by and kill epithelial cells expressing endogenous levels of MRI after infection with the invasive bacteria Shigella flexneri. In contrast, MAIT cells were not activated by epithelial cells infected by Salmonella enterica Typhimurium. Finally, MAIT cells are activated in human volunteers receiving an attenuated strain of Shigella dysenteriae-1 tested as a potential vaccine. Thus, in humans, MAIT cells are the most abundant T cell subset able to detect and kill bacteria infected cells. Human Mucosa-Associated Invariant T cells (MAIT) detect microbe-derived compounds presented by the MHC-like molecule, MR1. These foreign antigens are produced by a wide variety of microbes, including commensal and pathogenic bacteria or yeasts. MAIT cells expend shortly after birth and constitute the major antibacterial T cell subset described and, hence, could play important roles in infectious diseases. Here we show that MAIT cells recognize epithelial cells infected by the intestinal pathogen Shigella flexneri in a process requiring endogenous MR1, while the closely related bacterium Salmonella Tyhpimurium is not. Upon recognition, infected epithelial cells are efficiently lysed by MAIT cells. We also show that the triggering of CD161, a natural killer receptor highly expressed by MAIT cells, can modulate the cytokine but not the cytotoxic function of these cells. Finally, we provide evidence that MAIT cells are activated during the course of an experimental enteric infection in humans. Our study provides important insight on the antibacterial function of MAIT cells and their interaction with pathogenic bacterial species.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Philippe Sansonetti
- Institut Pasteur, Unité de Pathogénie Microbienne Moléculaire, U786, Paris, France
| | - Marie-Lise Gougeon
- Institut Pasteur, Unité Immunité Antivirale, Biothérapies et Vaccins, Paris, France
| | | | - Olivier Lantz
- Institut curie, Inserm U932, Paris, France
- Center of Clinical Investigations CICBT507 IGR/Curie, Paris, France
- Equipe labellisée de la ligue de lutte contre le cancer, Institut Curie, Paris, France
- * E-mail:
| |
Collapse
|
14
|
Simeonova I, Jaber S, Draskovic I, Bardot B, Fang M, Bouarich-Bourimi R, Lejour V, Charbonnier L, Soudais C, Bourdon JC, Huerre M, Londono-Vallejo A, Toledo F. Mutant mice lacking the p53 C-terminal domain model telomere syndromes. Cell Rep 2013; 3:2046-58. [PMID: 23770245 DOI: 10.1016/j.celrep.2013.05.028] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2012] [Revised: 04/01/2013] [Accepted: 05/17/2013] [Indexed: 11/29/2022] Open
Abstract
Mutations in p53, although frequent in human cancers, have not been implicated in telomere-related syndromes. Here, we show that homozygous mutant mice expressing p53Δ31, a p53 lacking the C-terminal domain, exhibit increased p53 activity and suffer from aplastic anemia and pulmonary fibrosis, hallmarks of syndromes caused by short telomeres. Indeed, p53Δ31/Δ31 mice had short telomeres and other phenotypic traits associated with the telomere disease dyskeratosis congenita and its severe variant the Hoyeraal-Hreidarsson syndrome. Heterozygous p53+/Δ31 mice were only mildly affected, but decreased levels of Mdm4, a negative regulator of p53, led to a dramatic aggravation of their symptoms. Importantly, several genes involved in telomere metabolism were downregulated in p53Δ31/Δ31 cells, including Dyskerin, Rtel1, and Tinf2, which are mutated in dyskeratosis congenita, and Terf1, which is implicated in aplastic anemia. Together, these data reveal that a truncating mutation can activate p53 and that p53 plays a major role in the regulation of telomere metabolism.
Collapse
Affiliation(s)
- Iva Simeonova
- Genetics of Tumor Suppression, Institut Curie, Centre de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Le Bourhis L, Guerri L, Dusseaux M, Martin E, Soudais C, Lantz O. Mucosal-associated invariant T cells: unconventional development and function. Trends Immunol 2011; 32:212-8. [PMID: 21459674 DOI: 10.1016/j.it.2011.02.005] [Citation(s) in RCA: 161] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2011] [Revised: 02/04/2011] [Accepted: 02/10/2011] [Indexed: 01/03/2023]
Abstract
Mucosal-associated invariant T (MAIT) cells are a population of T cells that display a semi-invariant T cell receptor (TCR) and are restricted by the evolutionarily conserved major histocompatibility complex related molecule, MR1. Here, we review recent knowledge of this T cell population. MAIT cells are abundant in human blood, gut and liver, and display an effector phenotype. They follow an atypical pathway of development and preferentially locate to peripheral tissues. Human and mouse MAIT cells react to bacterially infected cells in an MR1-dependent manner. They migrate to the infection site and can be protective in experimental infection models. MAIT cells secrete interferon-γ, and interleukin-17 under certain conditions. The species conservation, as well as the wide microbial reactivity, infer an important role for this cell population in immunity.
Collapse
Affiliation(s)
- Lionel Le Bourhis
- Institut Curie, Département de Biologie des Tumeurs, Paris, 75005, France
| | | | | | | | | | | |
Collapse
|
16
|
Le Bourhis L, Martin E, Péguillet I, Guihot A, Froux N, Coré M, Lévy E, Dusseaux M, Meyssonnier V, Premel V, Ngo C, Riteau B, Duban L, Robert D, Rottman M, Soudais C, Lantz O. Erratum: Corrigendum: Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol 2010. [DOI: 10.1038/ni1010-969a] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
17
|
Le Bourhis L, Martin E, Peguillet I, Guihot A, Coré M, Dusseaux M, Meyssonier V, Premel V, Ngo C, Robert D, Rottman M, Soudais C, Lantz O. Anti-bacterial Function of Mucosal Associated Invariant T Cells. Clin Immunol 2010. [DOI: 10.1016/j.clim.2010.03.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
18
|
Martin E, Treiner E, Duban L, Guerri L, Laude H, Toly C, Premel V, Devys A, Moura IC, Tilloy F, Cherif S, Vera G, Latour S, Soudais C, Lantz O. Stepwise development of MAIT cells in mouse and human. PLoS Biol 2009; 7:e54. [PMID: 19278296 PMCID: PMC2653554 DOI: 10.1371/journal.pbio.1000054] [Citation(s) in RCA: 451] [Impact Index Per Article: 30.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2008] [Accepted: 01/23/2009] [Indexed: 12/11/2022] Open
Abstract
Mucosal-associated invariant T (MAIT) cells display two evolutionarily conserved features: an invariant T cell receptor (TCR)α (iTCRα) chain and restriction by the nonpolymorphic class Ib major histocompatibility complex (MHC) molecule, MHC-related molecule 1 (MR1). MR1 expression on thymus epithelial cells is not necessary for MAIT cell development but their accumulation in the gut requires MR1 expressing B cells and commensal flora. MAIT cell development is poorly known, as these cells have not been found in the thymus so far. Herein, complementary human and mouse experiments using an anti-humanVα7.2 antibody and MAIT cell-specific iTCRα and TCRβ transgenic mice in different genetic backgrounds show that MAIT cell development is a stepwise process, with an intra-thymic selection followed by peripheral expansion. Mouse MAIT cells are selected in an MR1-dependent manner both in fetal thymic organ culture and in double iTCRα and TCRβ transgenic RAG knockout mice. In the latter mice, MAIT cells do not expand in the periphery unless B cells are added back by adoptive transfer, showing that B cells are not required for the initial thymic selection step but for the peripheral accumulation. In humans, contrary to natural killer T (NKT) cells, MAIT cells display a naïve phenotype in the thymus as well as in cord blood where they are in low numbers. After birth, MAIT cells acquire a memory phenotype and expand dramatically, up to 1%–4% of blood T cells. Finally, in contrast with NKT cells, human MAIT cell development is independent of the molecular adaptor SAP. Interestingly, mouse MAIT cells display a naïve phenotype and do not express the ZBTB16 transcription factor, which, in contrast, is expressed by NKT cells and the memory human MAIT cells found in the periphery after birth. In conclusion, MAIT cells are selected by MR1 in the thymus on a non-B non-T hematopoietic cell, and acquire a memory phenotype and expand in the periphery in a process dependent both upon B cells and the bacterial flora. Thus, their development follows a unique pattern at the crossroad of NKT and γδ T cells. White blood cells, or lymphocytes, play an important role in defending the body from infection and disease. T lymphocytes come in many varieties with diverse functions. Mucosal-associated invariant T (MAIT) cells constitute a subset of unconventional T lymphocytes, characterized by their invariant T cell receptor (TCR)α chain and their requirement for the nonpolymorphic class Ib (MHC) molecule, MR1. MAIT cells are extremely abundant in human blood and mucosae. Contrary to mainstream T cells, their development requires B cells and commensal microbial flora. To shed light on the little-understood MAIT cells, we used new tools, including an antibody that we recently developed to detect human MAIT cells, and we were able to show that MAIT cell development is a stepwise process, with an intra-thymic selection followed by peripheral expansion. We show that thymic selection is MR1 dependent but requires neither B cells nor the commensal flora, which are both necessary for the expansion in the periphery. In contrast with the other evolutionarily conserved invariant subset, the natural killer T (NKT) cells, we found that MAIT cells exit the thymus as “naïve” cells before becoming antigen-experienced memory cells and expanding in number to represent a significant 1%–4% of peripheral T cells in human blood. In mice, we found that MAIT cells remain naïve and do not expand substantially. We conclude that MAIT cell development follows a unique scheme, where, unlike NKT cells, MAIT cell selection and expansion are uncoupled events that are mediated by distinct cell types in different compartments. Mucosal-associated invariant T cells, the most abundant invariant T cell subset in humans, arise via a distinct developmental pathway that represents a hybrid of that seen for NKT and γδ T cells, two other unconventional T cell subsets.
Collapse
Affiliation(s)
- Emmanuel Martin
- Laboratoire d'Immunologie, Institut Curie, Paris, France
- INSERM U932, Institut Curie, Paris, France
| | - Emmanuel Treiner
- Laboratoire d'Immunologie, Institut Curie, Paris, France
- INSERM U932, Institut Curie, Paris, France
- Avenir INSERM U925, Faculté de Médecine, Amiens, France
| | - Livine Duban
- Laboratoire d'Immunologie, Institut Curie, Paris, France
- INSERM U932, Institut Curie, Paris, France
| | - Lucia Guerri
- Laboratoire d'Immunologie, Institut Curie, Paris, France
- INSERM U932, Institut Curie, Paris, France
| | - Hélène Laude
- Laboratoire d'Immunologie, Institut Curie, Paris, France
- INSERM U932, Institut Curie, Paris, France
| | - Cécile Toly
- Laboratoire d'Immunologie, Institut Curie, Paris, France
- INSERM U932, Institut Curie, Paris, France
| | - Virginie Premel
- Laboratoire d'Immunologie, Institut Curie, Paris, France
- INSERM U932, Institut Curie, Paris, France
| | - Anne Devys
- Établissement Français du Sang (EFS), Nantes, France
| | - Ivan C Moura
- Laboratoire d'Immunologie, Institut Curie, Paris, France
- INSERM U932, Institut Curie, Paris, France
| | - Florence Tilloy
- Laboratoire d'Immunologie, Institut Curie, Paris, France
- INSERM U932, Institut Curie, Paris, France
| | | | - Gabriella Vera
- Laboratoire d'Immunologie, Institut Curie, Paris, France
- INSERM U932, Institut Curie, Paris, France
| | - Sylvain Latour
- INSERM, Unité 768, Hôpital Necker-Enfants Malades, Paris, France
| | - Claire Soudais
- Laboratoire d'Immunologie, Institut Curie, Paris, France
- INSERM U932, Institut Curie, Paris, France
| | - Olivier Lantz
- Laboratoire d'Immunologie, Institut Curie, Paris, France
- INSERM U932, Institut Curie, Paris, France
- * To whom correspondence should be addressed. E-mail:
| |
Collapse
|
19
|
Huang S, Martin E, Kim S, Yu L, Soudais C, Fremont DH, Lantz O, Hansen TH. MR1 antigen presentation to mucosal-associated invariant T cells is highly conserved in mammals (78.7). The Journal of Immunology 2009. [DOI: 10.4049/jimmunol.182.supp.78.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
The development/expansion of mucosal associated invariant T cells or MAIT cells is dependent upon the class Ib molecule MR1, B cells and commensal flora. Additionally, MAIT cells express a canonical TCRα, a memory phenotype and rapidly secrete cytokines upon TCR ligation. Although these combined properties suggest that MAIT cells function as innate T cells in regulating mucosal immunity, this model has been difficult to test due to i) the paucity of MAIT cells that display MR1 specific activation in vitro, and ii) not knowing whether MR1 presents antigen. Here we show both mouse clones and human polyclonal MAIT cells display a high level of cross-reactivity on mammalian MR1 orthologs, but with differences consistent with limited ligand discrimination. Furthermore, acid eluates from recombinant or cellular MR1 proteins enhance MAIT cell activation in an MR1 specific and cross-species manner. Our combined findings demonstrate that the presentation pathway of MR1 to MAIT cells is highly physiologically conserved. These properties are reminiscent of pattern-like stimuli presented to previously described innate T cell populations and likely underlies the activated or memory phenotypes of MAIT cells.
This study was supported by grant AI046553 (Ted H. Hansen) from NIH, and in part by ANR MIME 2006 (Olivier Lantz) from the Inserm and ligue contre le cancer.
Collapse
Affiliation(s)
- Shouxiong Huang
- 1Pathology and Immunology, Washington University in St. Louis, St. Louis, MO
| | | | - Sojung Kim
- 1Pathology and Immunology, Washington University in St. Louis, St. Louis, MO
| | - Lawrence Yu
- 1Pathology and Immunology, Washington University in St. Louis, St. Louis, MO
| | | | - Daved H Fremont
- 1Pathology and Immunology, Washington University in St. Louis, St. Louis, MO
| | | | - Ted H Hansen
- 1Pathology and Immunology, Washington University in St. Louis, St. Louis, MO
| |
Collapse
|
20
|
Rottman M, Soudais C, Vogt G, Renia L, Emile JF, Decaluwe H, Gaillard JL, Casanova JL. IFN-gamma mediates the rejection of haematopoietic stem cells in IFN-gammaR1-deficient hosts. PLoS Med 2008; 5:e26. [PMID: 18232731 PMCID: PMC2214797 DOI: 10.1371/journal.pmed.0050026] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2007] [Accepted: 12/10/2007] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND Interferon-gamma receptor 1 (IFN-gammaR1) deficiency is a life-threatening inherited disorder, conferring predisposition to mycobacterial diseases. Haematopoietic stem cell transplantation (HSCT) is the only curative treatment available, but is hampered by a very high rate of graft rejection, even with intra-familial HLA-identical transplants. This high rejection rate is not seen in any other congenital disorders and remains unexplained. We studied the underlying mechanism in a mouse model of HSCT for IFN-gammaR1 deficiency. METHODS AND FINDINGS We demonstrated that HSCT with cells from a syngenic C57BL/6 Ifngr1+/+ donor engrafted well and restored anti-mycobacterial immunity in naive, non-infected C57BL/6 Ifngr1-/- recipients. However, Ifngr1-/- mice previously infected with Mycobacterium bovis bacillus Calmette-Guérin (BCG) rejected HSCT. Like infected IFN-gammaR1-deficient humans, infected Ifngr1-/- mice displayed very high serum IFN-gamma levels before HSCT. The administration of a recombinant IFN-gamma-expressing AAV vector to Ifngr1-/- naive recipients also resulted in HSCT graft rejection. Transplantation was successful in Ifngr1-/- x Ifng-/- double-mutant mice, even after BCG infection. Finally, efficient antibody-mediated IFN-gamma depletion in infected Ifngr1-/- mice in vivo allowed subsequent engraftment. CONCLUSIONS High serum IFN-gamma concentration is both necessary and sufficient for graft rejection in IFN-gammaR1-deficient mice, inhibiting the development of heterologous, IFN-gammaR1-expressing, haematopoietic cell lineages. These results confirm that IFN-gamma is an anti-haematopoietic cytokine in vivo. They also pave the way for HSCT management in IFN-gammaR1-deficient patients through IFN-gamma depletion from the blood. They further raise the possibility that depleting IFN-gamma may improve engraftment in other settings, such as HSCT from a haplo-identical or unrelated donor.
Collapse
Affiliation(s)
- Martin Rottman
- Laboratoire de Génétique Humaine des Maladies Infectieuses, INSERM, U550, Paris, France
- Université Paris René Descartes, Faculté de Médecine Necker-Enfants Malades, Paris, France
- Hôpital Raymond Poincaré, Faculté de Médecine Paris-Ile de France-Ouest, UPRES Sud, EA3647, Laboratoire de Microbiologie, Garches, France
| | - Claire Soudais
- Laboratoire de Génétique Humaine des Maladies Infectieuses, INSERM, U550, Paris, France
- Université Paris René Descartes, Faculté de Médecine Necker-Enfants Malades, Paris, France
| | - Guillaume Vogt
- Laboratoire de Génétique Humaine des Maladies Infectieuses, INSERM, U550, Paris, France
- Université Paris René Descartes, Faculté de Médecine Necker-Enfants Malades, Paris, France
| | - Laurent Renia
- Institut Cochin, INSERM, U567, Paris, France
- CNRS, UMR8104, Paris, France
- Université René Descartes, Hôpital Cochin, Paris, France
| | | | - Hélène Decaluwe
- Laboratoire de Génétique Humaine des Maladies Infectieuses, INSERM, U550, Paris, France
- Université Paris René Descartes, Faculté de Médecine Necker-Enfants Malades, Paris, France
| | - Jean-Louis Gaillard
- Hôpital Raymond Poincaré, Faculté de Médecine Paris-Ile de France-Ouest, UPRES Sud, EA3647, Laboratoire de Microbiologie, Garches, France
| | - Jean-Laurent Casanova
- Laboratoire de Génétique Humaine des Maladies Infectieuses, INSERM, U550, Paris, France
- Université Paris René Descartes, Faculté de Médecine Necker-Enfants Malades, Paris, France
- Unité d'Immunologie et Hématologie Pédiatriques, Hôpital Necker-Enfants Malades, Paris, France
| |
Collapse
|
21
|
Rottman M, Catherinot E, Hochedez P, Emile JF, Casanova JL, Gaillard JL, Soudais C. Importance of T cells, gamma interferon, and tumor necrosis factor in immune control of the rapid grower Mycobacterium abscessus in C57BL/6 mice. Infect Immun 2007; 75:5898-907. [PMID: 17875636 PMCID: PMC2168332 DOI: 10.1128/iai.00014-07] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Mycobacterium abscessus is an emerging rapidly growing mycobacterium that causes tuberculous-like lesions in humans. We studied the immune control of this organism in C57BL/6 mice challenged intravenously with 10(7) CFU. Bacteria were eliminated from both the spleen and the liver within 90 days, and liver histology showed organized granulomatous lesions. A T- and B-cell requirement was investigated by challenging Rag2-/-, Cd3epsilon-/-, and muMT-/- mice. Rag2-/- and Cd3epsilon-/- mice were significantly impaired in the ability to clear M. abscessus from the liver and spleen, and muMT-/- mice were significantly impaired in the ability to clear M. abscessus from the liver, suggesting that infection control was primarily T cell dependent in the spleen and both T and B cell dependent in the liver. The liver granulomatous response was similar to that of wild-type controls in muMT-/- mice but completely absent in Cd3epsilon-/- and Rag2-/- mice. We studied the involvement of gamma interferon (IFN-gamma) and tumor necrosis factor (TNF) by challenging C57BL/6 mice deficient in the IFN-gamma receptor (Ifngr1-/-) and in TNF (Tnf-/-). Ifngr1-/- mice were significantly impaired in M. abscessus control both in the spleen and in the liver, and granulomas were profoundly altered. The effect was even more substantial in Tnf-/- mice; they failed to control M. abscessus infection in the liver and died within 20 to 25 days after infection with many hepatic inflammatory foci and major lesions of ischemic necrosis in the liver and kidney. These features were not observed with the closely related species M. chelonae. T-cell immunity, IFN-gamma, and TNF are central factors for the control of M. abscessus in C57BL/6 mice, as they are for the control of pathogenic slowly growing mycobacteria.
Collapse
Affiliation(s)
- Martin Rottman
- Laboratoire de Microbiologie, Hôpital R. Poincaré, 104 Bd Raymond Poincaré, 92380 Garches, France.
| | | | | | | | | | | | | |
Collapse
|
22
|
Chapgier A, Boisson-Dupuis S, Jouanguy E, Vogt G, Feinberg J, Prochnicka-Chalufour A, Casrouge A, Yang K, Soudais C, Fieschi C, Santos OF, Bustamante J, Picard C, de Beaucoudrey L, Emile JF, Arkwright PD, Schreiber RD, Rolinck-Werninghaus C, Rösen-Wolff A, Magdorf K, Roesler J, Casanova JL. Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet 2007; 2:e131. [PMID: 16934001 PMCID: PMC1550284 DOI: 10.1371/journal.pgen.0020131] [Citation(s) in RCA: 148] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2006] [Accepted: 07/05/2006] [Indexed: 01/14/2023] Open
Abstract
The transcription factor signal transducer and activator of transcription-1 (STAT1) plays a key role in immunity against mycobacterial and viral infections. Here, we characterize three human STAT1 germline alleles from otherwise healthy patients with mycobacterial disease. The previously reported L706S, like the novel Q463H and E320Q alleles, are intrinsically deleterious for both interferon gamma (IFNG)–induced gamma-activating factor–mediated immunity and interferon alpha (IFNA)–induced interferon-stimulated genes factor 3–mediated immunity, as shown in STAT1-deficient cells transfected with the corresponding alleles. Their phenotypic effects are however mediated by different molecular mechanisms, L706S affecting STAT1 phosphorylation and Q463H and E320Q affecting STAT1 DNA-binding activity. Heterozygous patients display specifically impaired IFNG-induced gamma-activating factor–mediated immunity, resulting in susceptibility to mycobacteria. Indeed, IFNA-induced interferon-stimulated genes factor 3–mediated immunity is not affected, and these patients are not particularly susceptible to viral disease, unlike patients homozygous for other, equally deleterious STAT1 mutations recessive for both phenotypes. The three STAT1 alleles are therefore dominant for IFNG-mediated antimycobacterial immunity but recessive for IFNA-mediated antiviral immunity at the cellular and clinical levels. These STAT1 alleles define two forms of dominant STAT1 deficiency, depending on whether the mutations impair STAT1 phosphorylation or DNA binding. Mendelian susceptibility to mycobacterial disease is a rare syndrome. It is defined by the occurrence of severe disease caused by low virulence mycobacteria in otherwise healthy individuals, in whom antiviral immune response is not affected. Eleven known genetic defects, affecting five genes, have been involved in this type of deficient response to infection, involving immune-mediator molecules IL12 and interferon gamma: IL12B, IL12RB1, IFNGR1, IFNGR2, and STAT1. The signal transducer and activator of transcription-1 (STAT1) amino acid change L706S was previously shown to cause disease by impairing STAT1 phosphorylation. Here, we report two new STAT1 mutations that impair STAT1 DNA-binding activity. We show, by functional analysis of the three STAT1 mutant alleles, that they are intrinsically deleterious for both interferon gamma–induced antimycobacterial immunity, which is mediated through gamma-activated factor and for interferon alpha–induced antiviral immunity, which is mediated through interferon-stimulated genes factor 3. Interestingly, the three alleles are dominant for interferon gamma–induced gamma-activated factor–mediated antimycobacterial immunity, but recessive for interferon alpha–induced interferon-stimulated genes factor 3–mediated antiviral immunity at the cellular and clinical levels. These two new STAT1 alleles, which affect the binding of STAT1 to DNA, define distinct novel genetic causes of Mendelian susceptibility to mycobacterial disease and provide further insight into the molecular mechanism of disease.
Collapse
Affiliation(s)
- Ariane Chapgier
- Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes, INSERM U550, Necker Medical School, Paris, France, European Union
| | - Stéphanie Boisson-Dupuis
- Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes, INSERM U550, Necker Medical School, Paris, France, European Union
| | - Emmanuelle Jouanguy
- Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes, INSERM U550, Necker Medical School, Paris, France, European Union
- French-Chinese Laboratory of Genetics, Ruijin Hospital, Shanghai II University, Shanghai, People's Republic of China
| | - Guillaume Vogt
- Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes, INSERM U550, Necker Medical School, Paris, France, European Union
| | - Jacqueline Feinberg
- Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes, INSERM U550, Necker Medical School, Paris, France, European Union
| | - Ada Prochnicka-Chalufour
- Laboratory of MNR of Biomolecules, CNRS URA2185, Pasteur Institute, Paris, France, European Union
| | - Armanda Casrouge
- Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes, INSERM U550, Necker Medical School, Paris, France, European Union
| | - Kun Yang
- Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes, INSERM U550, Necker Medical School, Paris, France, European Union
- French-Chinese Laboratory of Genetics, Ruijin Hospital, Shanghai II University, Shanghai, People's Republic of China
| | - Claire Soudais
- Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes, INSERM U550, Necker Medical School, Paris, France, European Union
| | - Claire Fieschi
- Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes, INSERM U550, Necker Medical School, Paris, France, European Union
- Service of Clinical Immunology, Saint Louis Hospital, Paris, France, European Union
| | - Orchidée Filipe Santos
- Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes, INSERM U550, Necker Medical School, Paris, France, European Union
| | - Jacinta Bustamante
- Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes, INSERM U550, Necker Medical School, Paris, France, European Union
| | - Capucine Picard
- Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes, INSERM U550, Necker Medical School, Paris, France, European Union
- Center for the Study of Immunodeficiences, Necker Hospital, Paris, France, European Union
| | - Ludovic de Beaucoudrey
- Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes, INSERM U550, Necker Medical School, Paris, France, European Union
| | - Jean-François Emile
- Department of Pathology, Ambroise Paré Hospital, Boulogne, France, European Union
| | | | - Robert D Schreiber
- Department of Pathology and Immunology, Washington University, Saint Louis, Missouri, United States of America
| | | | - Angela Rösen-Wolff
- Department of Pediatrics, University Clinic Carl Gustav Carus, Dresden, Germany
| | - Klaus Magdorf
- Department of Pediatric Pneumology and Immunology, Charité, Humboldt University of Berlin, Berlin, Germany
| | - Joachim Roesler
- Department of Pediatrics, University Clinic Carl Gustav Carus, Dresden, Germany
| | - Jean-Laurent Casanova
- Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes, INSERM U550, Necker Medical School, Paris, France, European Union
- French-Chinese Laboratory of Genetics, Ruijin Hospital, Shanghai II University, Shanghai, People's Republic of China
- Pediatric Immunology Hematology Unit, Necker Hospital, Paris, France, European Union
- * To whom correspondence should be addressed. E-mail:
| |
Collapse
|
23
|
Catherinot E, Clarissou J, Etienne G, Ripoll F, Emile JF, Daffé M, Perronne C, Soudais C, Gaillard JL, Rottman M. Hypervirulence of a rough variant of the Mycobacterium abscessus type strain. Infect Immun 2006; 75:1055-8. [PMID: 17145951 PMCID: PMC1828507 DOI: 10.1128/iai.00835-06] [Citation(s) in RCA: 136] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
We isolated a rough variant of Mycobacterium abscessus CIP 104536T during experimental infection of mice. We show that this variant has lost the ability to produce glycopeptidolipids, is hyperlethal for C57BL/6 mice infected intravenously, and induces a strong tumor necrosis factor-alpha response by murine monocyte-derived macrophages.
Collapse
Affiliation(s)
- E Catherinot
- Laboratoire de Microbiologie, Hôpital Raymond Poincaré, 104 Bd Raymond Poincaré, 92380 Garches, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Catherinot E, Clarissou J, Etienne G, Ripoll F, Emile JF, Daffe M, Peronne C, Soudais C, Gaillard JL, Rottman M. 104 Hypervirulence d’un variant rugueux de la souche type de Mycobacterium abscessus. Rev Mal Respir 2006. [DOI: 10.1016/s0761-8425(06)71932-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
25
|
Vogt G, Chapgier A, Yang K, Chuzhanova N, Feinberg J, Fieschi C, Boisson-Dupuis S, Alcais A, Filipe-Santos O, Bustamante J, de Beaucoudrey L, Al-Mohsen I, Al-Hajjar S, Al-Ghonaium A, Adimi P, Mirsaeidi M, Khalilzadeh S, Rosenzweig S, de la Calle Martin O, Bauer TR, Puck JM, Ochs HD, Furthner D, Engelhorn C, Belohradsky B, Mansouri D, Holland SM, Schreiber RD, Abel L, Cooper DN, Soudais C, Casanova JL. Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet 2005; 37:692-700. [PMID: 15924140 DOI: 10.1038/ng1581] [Citation(s) in RCA: 176] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2005] [Accepted: 04/25/2005] [Indexed: 11/09/2022]
Abstract
Mutations involving gains of glycosylation have been considered rare, and the pathogenic role of the new carbohydrate chains has never been formally established. We identified three children with mendelian susceptibility to mycobacterial disease who were homozygous with respect to a missense mutation in IFNGR2 creating a new N-glycosylation site in the IFNgammaR2 chain. The resulting additional carbohydrate moiety was both necessary and sufficient to abolish the cellular response to IFNgamma. We then searched the Human Gene Mutation Database for potential gain-of-N-glycosylation missense mutations; of 10,047 mutations in 577 genes encoding proteins trafficked through the secretory pathway, we identified 142 candidate mutations ( approximately 1.4%) in 77 genes ( approximately 13.3%). Six mutant proteins bore new N-linked carbohydrate moieties. Thus, an unexpectedly high proportion of mutations that cause human genetic disease might lead to the creation of new N-glycosylation sites. Their pathogenic effects may be a direct consequence of the addition of N-linked carbohydrate.
Collapse
Affiliation(s)
- Guillaume Vogt
- Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes INSERM U550, Necker Medical School, 156 rue de Vaugirard, 75015 Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
de Saint Basile G, Geissmann F, Flori E, Uring-Lambert B, Soudais C, Cavazzana-Calvo M, Durandy A, Jabado N, Fischer A, Le Deist F. Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3. J Clin Invest 2004; 114:1512-7. [PMID: 15546002 PMCID: PMC525745 DOI: 10.1172/jci22588] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2004] [Accepted: 08/24/2004] [Indexed: 02/02/2023] Open
Abstract
We investigated the molecular mechanism underlying a severe combined immunodeficiency characterized by the selective and complete absence of T cells. The condition was found in 5 patients and 2 fetuses from 3 consanguineous families. Linkage analysis performed on the 3 families revealed that the patients were carrying homozygous haplotypes within the 11q23 region, in which the genes encoding the gamma, delta, and epsilon subunits of CD3 are located. Patients and affected fetuses from 2 families were homozygous for a mutation in the CD3D gene, and patients from the third family were homozygous for a mutation in the CD3E gene. The thymus from a CD3delta-deficient fetus was analyzed and revealed that T cell differentiation was blocked at entry into the double positive (CD4+CD8+) stage with the accumulation of intermediate CD4-single positive cells. This indicates that CD3delta plays an essential role in promoting progression of early thymocytes toward double-positive stage. Altogether, these findings extend the known molecular mechanisms underlying severe combined immunodeficiency to a new deficiency, i.e., CD3epsilon deficiency, and emphasize the essential roles played by the CD3epsilon and CD3delta subunits in human thymocyte development, since these subunits associate with both the pre-TCR and the TCR.
Collapse
|
27
|
Basile GDS, Geissmann F, Flori E, Uring-Lambert B, Soudais C, Cavazzana-Calvo M, Durandy A, Jabado N, Fischer A, Deist FL. Severe combined immunodeficiency caused by deficiency in either the δ or the ε subunit of CD3. J Clin Invest 2004. [DOI: 10.1172/jci200422588] [Citation(s) in RCA: 115] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
|
28
|
Abstract
Numerous genetic and environmental causes, variable pathophysiologies, and the blood-brain barrier create a formidable challenge for the study and treatment of neurodegenerative diseases affecting the central nervous system. Although there are many intracellular strategies to address neurodegeneration, for example, which transgene to use, one fundamental criterion for the long-term survival of neurons may be their genetic modification. Here, we describe the generation and in vivo efficacy of helper-dependent canine adenovirus (CAV-2) vectors that preferentially transduced neurons and efficiently trafficked via axonal retrograde transport. We used a flexible strategy and the synergy between Cre/loxP and nonlethal packaging-defective helper vectors to generate high titer helper-dependent vector stocks. One year after striatal injections in the rat brain, we found stable, high-level expression in striatal neurons, ~50% of the dopaminergic neurons of the substantia nigra, and the cholinergic neurons in the basal nuclei of Meynert. Due to the intrinsic properties of helper-dependent CAV-2 vectors (27-kb cloning capacity; low preexisting, innate, and induced immunogenicity; retrograde transport; and long-term transgene expression), they will aid fundamental and applied studies in neurobiology. Moreover, helper-dependent CAV-2 vectors may be clinically relevant for the treatment of many neurodegenerative diseases.
Collapse
Affiliation(s)
- Claire Soudais
- INSERM Unit 550, Faculté de Médecine Necker, Paris 75015, France
| | | | | |
Collapse
|
29
|
Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K, Soudais C, Dupuis S, Feinberg J, Fieschi C, Elbim C, Hitchcock R, Lammas D, Davies G, Al-Ghonaium A, Al-Rayes H, Al-Jumaah S, Al-Hajjar S, Al-Mohsen IZ, Frayha HH, Rucker R, Hawn TR, Aderem A, Tufenkeji H, Haraguchi S, Day NK, Good RA, Gougerot-Pocidalo MA, Ozinsky A, Casanova JL. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003; 299:2076-9. [PMID: 12637671 DOI: 10.1126/science.1081902] [Citation(s) in RCA: 659] [Impact Index Per Article: 31.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Members of the Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) superfamily share an intracytoplasmic Toll-IL-1 receptor (TIR) domain, which mediates recruitment of the interleukin-1 receptor-associated kinase (IRAK) complex via TIR-containing adapter molecules. We describe three unrelated children with inherited IRAK-4 deficiency. Their blood and fibroblast cells did not activate nuclear factor kappaB and mitogen-activated protein kinase (MAPK) and failed to induce downstream cytokines in response to any of the known ligands of TIR-bearing receptors. The otherwise healthy children developed infections caused by pyogenic bacteria. These findings suggest that, in humans, the TIR-IRAK signaling pathway is crucial for protective immunity against specific bacteria but is redundant against most other microorganisms.
Collapse
Affiliation(s)
- Capucine Picard
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes-INSERM U550, Faculté Necker, 156 rue de Vaugirard, 75015 Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
The retrograde transport and transynaptic transfer properties of the nontoxic tetanus toxin C-fragment (TTC) can be used to visualize specific neural pathways or to deliver biomolecules in the central nervous system (CNS). Here we tested different delivery techniques to explore the potential use of a new GFP-TTC fusion construct for use as a genetic tracer in vivo. Plasmids encoding GFP-TTC were targeted to brain regions using intracerebral grafted transfected cells or adenoviral transduction. Transport was monitored using GFP fluorescence. We show that following GFP-TTC synthesis in grafted transfected cells, the TTC fragment alone, with no signal peptide, is necessary and sufficient to provide secretion and uptake of the fusion protein into neighboring neurons around the injection site. Using an adenoviral vector to express the fusion protein into brain neurons, we show that transduced neurons can deliver the fusion protein specifically into connected neurons, demonstrating that synaptic transfer in the CNS can be visualized with GFP-TTC.
Collapse
Affiliation(s)
- Karima Kissa
- Unité d'Embryologie Moléculaire, URA 1947 CNRS, Institut Pasteur, 25 rue du Dr Roux, F-75724 Paris Cedex 15, France
| | | | | | | | | | | | | |
Collapse
|
31
|
Picard C, Fieschi C, Altare F, Al-Jumaah S, Al-Hajjar S, Feinberg J, Dupuis S, Soudais C, Al-Mohsen IZ, Génin E, Lammas D, Kumararatne DS, Leclerc T, Rafii A, Frayha H, Murugasu B, Wah LB, Sinniah R, Loubser M, Okamoto E, Al-Ghonaium A, Tufenkeji H, Abel L, Casanova JL. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet 2002; 70:336-48. [PMID: 11753820 PMCID: PMC384913 DOI: 10.1086/338625] [Citation(s) in RCA: 211] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2001] [Accepted: 11/05/2001] [Indexed: 11/03/2022] Open
Abstract
Interleukin-12 (IL12) is a cytokine that is secreted by activated phagocytes and dendritic cells and that induces interferon-gamma production by natural-killer and T lymphocytes. It consists of two subunits, p35 and p40, which are encoded by IL12A and IL12B, respectively. The first reported patient with a genetic cytokine disorder was a Pakistani child, who was homozygous for a large loss-of-function deletion (g.482+82_856-854del) in IL12B. This IL12-deficient child suffered from infections caused by bacille Calmette-Guérin (BCG) and Salmonella enteritidis. We herein report 12 additional patients from five other kindreds. In one kindred from India, the same large deletion that was described elsewhere (g.482+82_856-854del) was identified. In four kindreds from Saudi Arabia, a recessive loss-of-function frameshift insertion (g.315_316insA) was found. A conserved haplotype encompassing the IL12B gene suggested that a founder effect accounted for the recurrence of each mutation. The two founder mutational events-g.482+82_856-854del and g.315_316insA-were estimated to have occurred approximately 700 and approximately 1,100 years ago, respectively. Among a total of 13 patients with IL12 deficiency, 1 child had salmonellosis only and 12 suffered from clinical disease due to BCG or environmental nontuberculous mycobacteria. One patient also had clinical disease caused by virulent Mycobacterium tuberculosis, five patients had clinical disease caused by Salmonella serotypes, and one patient had clinical disease caused by Nocardia asteroides. The clinical outcome varies from case to case, since five patients (aged 2-11 years) died of overwhelming infection, whereas eight patients (aged 3-12 years) are still in good health and are not currently taking antibiotics. In conclusion, IL12 deficiency is not limited to a single kindred, shows significant variability of outcome, and should be considered in the genetic diagnosis of patients with mycobacteriosis and/or salmonellosis. To date, two founder IL12B mutations have been identified, accounting for the recurrence of a large deletion and a small insertion within populations from the Indian subcontinent and from the Arabian Peninsula, respectively.
Collapse
Affiliation(s)
- Capucine Picard
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Claire Fieschi
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Frédéric Altare
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Suliman Al-Jumaah
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Sami Al-Hajjar
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Jacqueline Feinberg
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Stéphanie Dupuis
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Claire Soudais
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Ibrahim Zaid Al-Mohsen
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Emmanuelle Génin
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - David Lammas
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Dinakantha S. Kumararatne
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Tony Leclerc
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Arash Rafii
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Husn Frayha
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Belinda Murugasu
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Lee Bee Wah
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Raja Sinniah
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Michael Loubser
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Emi Okamoto
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Abdulaziz Al-Ghonaium
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Haysam Tufenkeji
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Laurent Abel
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| | - Jean-Laurent Casanova
- Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes INSERM U550, Faculté de Médecine Necker, and Unité d’Immunologie et d’Hématologie Pédiatriques, Hôpital Necker-Enfants Malades Paris; Department of Paediatrics, King Faisal Specialist Hospital and Research Center, and Department of Paediatrics, Security Forces Hospital, Riyadh, Saudi Arabia; Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Le Kremlin Bicêtre, France; Medical Research Council Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham, United Kingdom; Department of Clinical Immunology, Addenbrookes Hospital National Health Service Trust, Cambridge; and Departments of Paediatrics and Pathology, National University Hospital of Singapore, Singapore
| |
Collapse
|
32
|
Soudais C, Laplace-Builhe C, Kissa K, Kremer EJ. Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo. FASEB J 2001; 15:2283-5. [PMID: 11511531 DOI: 10.1096/fj.01-0321fje] [Citation(s) in RCA: 178] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
In the central nervous system (CNS), there are innate obstacles to the modification of neurons: their relative low abundance versus glia and oligodendrocytes, the inaccessibility of certain target populations, and the volume one can inject safely. Our aim in this study was to characterize the in vivo efficacy of a novel viral vector derived from a canine adenovirus (CAV-2). Here we show that CAV-2 preferentially transduced i) rat olfactory sensory neurons; ii) rodent CNS neurons in vitro and in vivo; and, more clinically relevant, iii) neurons in organotypic slices of human cortical brain. CAV-2 also showed a high disposition for retrograde axonal transport in vivo. We examined the molecular basis of neuronal targeting by CAV-2 and suggest that due to CAR (coxsackie adenovirus receptor) expression on neuronal cells-and not oligodendrocytes, glia, myofibers, and nasal epithelial cells-CAV-2 vectors transduced neurons preferentially in these diverse tissues.
Collapse
Affiliation(s)
- C Soudais
- Généthon III/CNRS 1923, Evry, France
| | | | | | | |
Collapse
|
33
|
Sarukhan A, Soudais C, Danos O, Jooss K. Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors. J Gene Med 2001; 3:260-70. [PMID: 11437331 DOI: 10.1002/jgm.175] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND We have previously demonstrated that recombinant adeno-associated virus vectors expressing the influenza virus hemagglutinin (rAAV-HA) in skeletal muscle results in T-cell priming and muscle fiber destruction due to cross-presentation of HA by dendritic cells (DC). Based on controversial observations concerning the stability of non-self proteins expressed from rAAV vectors it is important to understand the factors influencing cross-presentation of transgene products following rAAV mediated gene transfer, in order to be able to use this vector safely in the clinic. METHODS In order to understand the factors influencing in vivo cross-presentation of non-self proteins, we have retargeted the immunogenic lacZ protein in the context of rAAV from the cytoplasm to the cell surface and studied the activation of LacZ specific immune responses following intramuscular mediated gene transfer. In addition, using tools available for studying in vitro HA-specific T-cell activation, our aim was to identify the cell types involved in class I and class II restricted cross-presentation as well as the nature of the cross-presented material. RESULTS By retargeting the lacZ protein in the context of rAAV to the cell membrane, we found that one of the factors influencing the efficiency of cross-presentation of non-self antigens is the localization of the transgene product within the target cells. Following rAAV-LacZ mediated gene transfer to the muscle we demonstrated that the membrane-bound form of LacZ resulted in target cell destruction, which is in stark contrast to the stability observed with rAAV-LacZ vectors expressing the cytoplasmic form of LacZ. Using an in vitro assay, we were able to show that dendritic cells (DC) in addition to B-cells cross-presented HA to class II restricted T-cells whereas only the former were able to activate class I restricted CD8+ T-cells. High-dose antigens were needed for efficient class I restricted T-cell priming, whereas class II restricted T-cells were activated by less antigen. CONCLUSION The present results indicate that immune responses to non-self antigens expressed from rAAV vectors depend on the accessibility of such antigens to different local antigen-presenting cells.
Collapse
Affiliation(s)
- A Sarukhan
- Institut Necker, INSERM 345, Paris, France
| | | | | | | |
Collapse
|
34
|
Abstract
The cis-acting packaging domain in adenovirus serotype 5 (Ad5) is a series of redundant, albeit not functionally equivalent, "A-repeats" made up of the consensus sequence 5'-TTTGN(8)CG-3'. A-repeats may bind trans-acting factors that direct packaging of the adenovirus genome into the preformed capsid. To try to understand this basic mechanism, we examined the packaging domain from a nonhuman adenovirus. We delimited the canine adenovirus type 2 (CAV-2) packaging domain to within 156 bp via a conditional mutation based on the Cre/loxP excision. Using an insertion, deletion, and substitution strategy, we generated packaging-defective CAV-2 vectors. Our results demonstrate that, like Ad5, CAV-2 cis-acting packaging sequences are located near the left inverted terminal repeat and are redundant, but not functionally equivalent. However, the bipartite motif found in Ad5 is present only once in CAV-2 and deletion of it caused only a minor variation in the packaging efficiency. We have identified at least four functional cis-acting packaging sequences in CAV-2. The CAV-2 vectors that we generated were not replication-defective in an E1-transcomplementing cell line and as heat stable as the parental vectors that did not contain mutations.
Collapse
Affiliation(s)
- C Soudais
- Généthon III and CNRS URA 1923, Evry, France
| | | | | |
Collapse
|
35
|
Abstract
Primary immunodeficiency diseases (PID) are attractive candi dates for a gene therapy approach because many of these disorders convey a poor prognosis while a number of the genes mutated in these conditions have been identified. Gene transfer into hematopoietic stem cells (HSC) should, in theory, lead to a cure of the disease. There are, however, a number of limitations mostly related to the failure of clinically available vectors to enable transgene integration into HSC. Nevertheless PID due to a gene defect leading to failure of cell development could be amenable to gene therapy given the selective advantage conferred to transgene expression in progenitor cells. Terminally differentiated cells are, however, long lived, as is the case for T lymphocytes. This concept led to the first gene therapy trials for adenosine deaminase (ADA) deficiency several years ago. Results were in part disappointing mostly because of the concomitant substitutive treatment by polyethylene glycol-ADA. However, recent application to X-linked severe combined immunodeficiency (gamma(c) deficiency) turned out to be efficient at least on a relatively short term basis (i.e. one year so far). These results demonstrate that this concept is valid and can be the basis for the treatment of other forms of severe T-cell immunodeficiencies. Obviously, development of vectors (lentiviruses) able to efficiently target HSC could in the future considerably enlarge the field of PID treatable by gene transfer.
Collapse
Affiliation(s)
- A Fischer
- INSERM U 429, H pital Necker, Paris, France.
| | | | | | | | | | | | | |
Collapse
|
36
|
Soudais C, Boutin S, Hong SS, Chillon M, Danos O, Bergelson JM, Boulanger P, Kremer EJ. Canine adenovirus type 2 attachment and internalization: coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway. J Virol 2000; 74:10639-49. [PMID: 11044108 PMCID: PMC110938 DOI: 10.1128/jvi.74.22.10639-10649.2000] [Citation(s) in RCA: 98] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The best-characterized receptors for adenoviruses (Ads) are the coxsackievirus-Ad receptor (CAR) and integrins alpha(v)beta(5) and alpha(v)beta(3), which facilitate entry. The alpha(v) integrins recognize an Arg-Gly-Asp (RGD) motif found in some extracellular matrix proteins and in the penton base in most human Ads. Using a canine adenovirus type 2 (CAV-2) vector, we found that CHO cells that express CAR but not wild-type CHO cells are susceptible to CAV-2 transduction. Cells expressing alpha(M)beta(2) integrins or major histocompatibility complex class I (MHC-I) molecules but which do not express CAR were not transduced. Binding assays showed that CAV-2 attaches to a recombinant soluble form of CAR and that Ad type 5 (Ad5) fiber, penton base, and an anti-CAR antibody partially blocked attachment. Using fluorescently labeled CAV-2 particles, we found that in some cells nonpermissive for transduction, inhibition was at the point of internalization and not attachment. The transduction efficiency of CAV-2, which lacks an RGD motif, surprisingly mimicked that of Ad5 when tested in cells selectively expressing alpha(v)beta(5) and alpha(v)beta(3) integrins. Our results demonstrate that CAV-2 transduction is augmented by CAR and possibly by alpha(v)beta(5), though transduction can be CAR and alpha(v)beta(3/5) independent but is alpha(M)beta(2), MHC-I, and RGD independent, demonstrating a transduction mechanism which is distinct from that of Ad2/5.
Collapse
Affiliation(s)
- C Soudais
- Généthon III and CNRS URA 1923, Evry, CNRS UMR 5537, Lyon, France
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Soudais C, Shiho T, Sharara LI, Guy-Grand D, Taniguchi T, Fischer A, Di Santo JP. Stable and functional lymphoid reconstitution of common cytokine receptor gamma chain deficient mice by retroviral-mediated gene transfer. Blood 2000; 95:3071-7. [PMID: 10807771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
Abstract
Mutations in the gene encoding the common cytokine receptor gamma chain (gamma(c)) are responsible for human X-linked severe combined immunodeficiency disease (SCIDX1). We have used a gamma(c)-deficient mouse model to test the feasibility and potential toxicity of gamma(c) gene transfer as a therapy for SCIDX1. A retrovirus harboring the murine gamma(c) chain was introduced into gamma(c)-deficient bone marrow cells, which were then transplanted into alymphoid RAG2/gamma(c) double-deficient recipient mice. Circulating lymphocytes appeared 4 weeks postgraft and achieved steady-state levels by 8 weeks. The mature lymphocytes present in the grafted mice had integrated the gamma(c) transgene, expressed gamma(c) transcripts, and were able to proliferate in response to gamma(c)-dependent cytokines. The gamma(c)-transduced animals demonstrated (1) normal levels of immunoglobulin subclasses, including immunoglobulin G1 (IgG1) and IgG2a (which are severely decreased in gamma(c)(-) mice); (2) the ability to mount an antigen-specific, T-dependent antibody response showing effective in vivo T-B cell cooperation, and (3) the presence of gut-associated cryptopatches and intraepithelial lymphocytes. Importantly, peripheral B and T cells were still present 47 weeks after a primary graft, and animals receiving a secondary graft of gamma(c)-transduced bone marrow cells demonstrated peripheral lymphoid reconstitution. That gamma(c) gene transfer to hematopoietic precursor cells can correct the immune system abnormalities in gamma(c)(-) mice supports the feasibility of in vivo retroviral gene transfer as a treatment for human SCIDX1.
Collapse
Affiliation(s)
- C Soudais
- INSERM U429, Hôpital Necker, Paris, France
| | | | | | | | | | | | | |
Collapse
|
38
|
Colucci F, Soudais C, Rosmaraki E, Vanes L, Tybulewicz VLJ, Di Santo JP. Dissecting NK Cell Development Using a Novel Alymphoid Mouse Model: Investigating the Role of the c- abl Proto-Oncogene in Murine NK Cell Differentiation. The Journal of Immunology 1999. [DOI: 10.4049/jimmunol.162.5.2761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
NK lymphocytes participate in both innate and adaptive immunity by their prompt secretion of cytokines including IFN-γ, which activates macrophages, and by their ability to lyse virally infected cells and tumor cells without prior sensitization. Although these characteristics of NK cells are well documented, little is known about the genetic program that orchestrates NK development or about the signaling pathways that trigger NK effector functions. By crossing NK-deficient common γ-chain (γc) and recombinase activating gene (RAG)-2 mutant mice, we have generated a novel alymphoid (B−, T−, and NK−) mouse strain (RAG2/γc) suitable for NK complementation in vivo. The role of the c-abl proto-oncogene in murine NK cell differentiation has been addressed in hemopoietic chimeras generated using RAG2/γc mice reconstituted with c-abl−/− fetal liver cells. The phenotypically mature NK cells that developed in the absence of c-abl were capable of lysing tumor targets, recognizing “missing self,” and performing Ab-dependent cellular cytotoxicity. Taken together, these results exclude any essential role for c-abl in murine NK cell differentiation in vivo. The RAG2/γc model thereby provides a novel approach to establish a genetic map of NK cell development.
Collapse
Affiliation(s)
- Francesco Colucci
- *Institut National de la Santé et de la Recherche Médicale, Unite 429, Hôpital Necker-Enfants Malades, Paris, France; and
| | - Claire Soudais
- *Institut National de la Santé et de la Recherche Médicale, Unite 429, Hôpital Necker-Enfants Malades, Paris, France; and
| | - Eleftheria Rosmaraki
- *Institut National de la Santé et de la Recherche Médicale, Unite 429, Hôpital Necker-Enfants Malades, Paris, France; and
| | - Lesley Vanes
- †National Institute for Medical Research, The Ridgeway, Mill Hill, London, United Kingdom
| | | | - James P. Di Santo
- *Institut National de la Santé et de la Recherche Médicale, Unite 429, Hôpital Necker-Enfants Malades, Paris, France; and
| |
Collapse
|
39
|
Colucci F, Soudais C, Rosmaraki E, Vanes L, Tybulewicz VL, Di Santo JP. Dissecting NK cell development using a novel alymphoid mouse model: investigating the role of the c-abl proto-oncogene in murine NK cell differentiation. J Immunol 1999; 162:2761-5. [PMID: 10072522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
NK lymphocytes participate in both innate and adaptive immunity by their prompt secretion of cytokines including IFN-gamma, which activates macrophages, and by their ability to lyse virally infected cells and tumor cells without prior sensitization. Although these characteristics of NK cells are well documented, little is known about the genetic program that orchestrates NK development or about the signaling pathways that trigger NK effector functions. By crossing NK-deficient common gamma-chain (gammac) and recombinase activating gene (RAG)-2 mutant mice, we have generated a novel alymphoid (B-, T-, and NK-) mouse strain (RAG2/gammac) suitable for NK complementation in vivo. The role of the c-abl proto-oncogene in murine NK cell differentiation has been addressed in hemopoietic chimeras generated using RAG2/gammac mice reconstituted with c-abl-/- fetal liver cells. The phenotypically mature NK cells that developed in the absence of c-abl were capable of lysing tumor targets, recognizing "missing self," and performing Ab-dependent cellular cytotoxicity. Taken together, these results exclude any essential role for c-abl in murine NK cell differentiation in vivo. The RAG2/gammac model thereby provides a novel approach to establish a genetic map of NK cell development.
Collapse
Affiliation(s)
- F Colucci
- Institut National de la Santé et de la Recherche Médicale, Unite 429, Hôpital Necker-Enfants Malades, Paris, France
| | | | | | | | | | | |
Collapse
|
40
|
Fischer A, de Saint Basile G, Cavazzana-Calvo M, Soudais C, Di Santo J, Cavazzana-Calvo M. Thérapie génique des déficits immunitaires : approche expérimentale et premiers résultats cliniques. Med Sci (Paris) 1999. [DOI: 10.4267/10608/1399] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
41
|
Kuo CT, Morrisey EE, Anandappa R, Sigrist K, Lu MM, Parmacek MS, Soudais C, Leiden JM. GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev 1997; 11:1048-60. [PMID: 9136932 DOI: 10.1101/gad.11.8.1048] [Citation(s) in RCA: 765] [Impact Index Per Article: 28.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Previous studies have suggested that the GATA4 transcription factor plays an important role in regulating mammalian cardiac development. In the studies described in this report we have used gene targeting to produce GATA4-deficient mice. Homozygous GATA4-deficient (GATA4-/-) mice died between 8.5 and 10.5 days post coitum (dpc). GATA4-/- embryos displayed severe defects in both rostral-to-caudal and lateral-to-ventral folding, which were reflected in a generalized disruption of the ventral body pattern. This resulted in the defective formation of an organized foregut and anterior intestinal pore, the failure to close both the amniotic cavity and yolk sac, and the uniform lack of a ventral pericardial cavity and heart tube. Analysis of cardiac development in the GATA4-/- mice demonstrated that these embryos developed splanchnic mesoderm, which differentiated into primitive cardiac myocytes that expressed contractile proteins. However, consistent with the observed defect in ventral morphogenesis, these GATA4-/- procardiomyocytes failed to migrate to the ventral midline to form a linear heart tube and instead formed aberrant cardiac structures in the anterior and dorsolateral regions of the embryo. The defect in ventral migration of the GATA4-/- procardiomyocytes was not cell intrinsic because GATA4-/- cardiac myocytes and endocardial cells populated the hearts of GATA4-/- -C57BL/6 chimeric mice. Taken together, these results demonstrated that GATA4 is not essential for the specification of the cardiac cell lineages. However, they define a critical role for GATA4 in regulating the rostral-to-caudal and lateral-to-ventral folding of the embryo that is needed for normal cardiac morphogenesis.
Collapse
Affiliation(s)
- C T Kuo
- Department of Medicine, The University of Chicago, Illinois 60637, USA
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Soudais C, Bielinska M, Heikinheimo M, MacArthur CA, Narita N, Saffitz JE, Simon MC, Leiden JM, Wilson DB. Targeted mutagenesis of the transcription factor GATA-4 gene in mouse embryonic stem cells disrupts visceral endoderm differentiation in vitro. Development 1995; 121:3877-88. [PMID: 8582296 DOI: 10.1242/dev.121.11.3877] [Citation(s) in RCA: 189] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Transcription factor GATA-4 belongs to a family of zinc finger proteins involved in lineage determination. GATA-4 is first expressed in yolk sac endoderm of the developing mouse and later in cardiac tissue, gut epithelium and gonads. To delineate the role of this transcription factor in differentiation and early development, we studied embryoid bodies derived from mouse embryonic stem (ES) cells in which both copies of the Gata-4 gene were disrupted. Light and electron microscopy demonstrated that embryoid bodies formed from wild-type and heterozygous deficient ES cells were covered with a layer of visceral yolk sac endoderm, whereas no yolk sac endoderm was evident on the surface of the homozygous deficient embryoid bodies. Independently selected homozygous deficient cell lines displayed this distinctive phenotype, suggesting that it was not an artifact of clonal variation. Biochemical markers of visceral endoderm formation, such as alpha-feto-protein, hepatocyte nuclear factor-4 and binding sites for Dolichos biflorus agglutinin, were absent from the homozygous deficient embryoid bodies. Examination of other differentiation markers in the mutant embryoid bodies, studies of ES cell-derived teratocarcinomas and chimeric mouse analysis demonstrated that GATA-4-deficient ES cells have the capacity to differentiate along other lineages. We conclude that, under in vitro conditions, disruption of the Gata-4 gene results in a specific block in visceral endoderm formation. These homozygous deficient cells should yield insights into the regulation of yolk sac endoderm development and the factors expressed by visceral endoderm that influence differentiation of adjoining ectoderm/mesoderm.
Collapse
Affiliation(s)
- C Soudais
- Department of Medicine, Howard Hughes Medical Institute, University of Chicago School of Medicine, IL, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Soudais C, Lisowska-Grospierre B. Déficits immunitaires liés à un défaut d'expression du récepteur pour l'antigène. Med Sci (Paris) 1993. [DOI: 10.4267/10608/2988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
44
|
Soudais C, de Villartay JP, Le Deist F, Fischer A, Lisowska-Grospierre B. Independent mutations of the human CD3-epsilon gene resulting in a T cell receptor/CD3 complex immunodeficiency. Nat Genet 1993; 3:77-81. [PMID: 8490660 DOI: 10.1038/ng0193-77] [Citation(s) in RCA: 74] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The T-cell receptor (TCR) is composed of two glycoproteins (alpha and beta or gamma and delta) associated with four invariant polypeptides (CD3-gamma, delta, epsilon and zeta). The majority of TCR/CD3 complexes contain six polypeptide chains, and although there is some flexibility in the complex subunit stoichiometry the CD3-epsilon chain is central to CD3 core assembly and full complex formation. We have described previously defective expression of the TCR/CD3 complex in an immunodeficient child. We now report that two independent CD3-epsilon gene mutations present in the parents have segregated in the patient, leading to defective CD3-epsilon chain synthesis and preventing normal association and membrane expression of the TCR/CD3 complex.
Collapse
Affiliation(s)
- C Soudais
- INSERM U 132, Hôpital Necker Enfants Malades, Paris, France
| | | | | | | | | |
Collapse
|
45
|
Thoenes G, Soudais C, le Deist F, Griscelli C, Fischer A, Lisowska-Grospierre B. Structural analysis of low TCR-CD3 complex expression in T cells of an immunodeficient patient. J Biol Chem 1992; 267:487-93. [PMID: 1370449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/25/2023] Open
Abstract
Normal membrane expression of the T cell receptor (TCR) depends on the coordinated synthesis and assembly of all seven proteins composing the complex, i.e. the TCR alpha and beta chains, the CD3 gamma, delta, and epsilon chains, and the zeta-zeta or zeta-eta dimer. In an experimental TCR membrane-defective T cell variant (Sussman, J. L., Bonifacino, J. S., Lippincott-Schwartz, J., Weissman, A. M., Saito, T., Klausner, R. D., and Ashwell, J. D. (1988) Cell 52, 85-95) and in two siblings whose lymphocytes express only a low level of the TCR/CD3 complex (Alarcon, B., Berkhout, B., Breitmeyer, J., and Terhorst, C. (1988) N. Engl. J. Med. 319, 1203-1208), a defect in zeta chain synthesis and/or assembly was thought to account for the defective membrane synthesis of the whole complex. We report on another immunodeficient patient whose T lymphocytes express the T cell receptor at one-tenth of normal fluorescence intensity and are not triggered to proliferate in vitro by anti-CD3 or anti-CD2 antibodies. Biochemical analysis of the patient's surface-iodinated peripheral blood lymphocytes failed to detect TCR alpha and beta, or CD3 gamma, delta, and epsilon proteins but revealed the presence of the zeta homodimer (probably as a result of the high proportion of natural killer cells). In the cytoplasm, TCR alpha and beta proteins and the zeta chain were detected, but, using monoclonal anti-CD3 antibodies, the CD3 gamma, delta, and epsilon chains were not. In addition, the CD3 epsilon chain was not detected with polyclonal antiserum in a very sensitive Western blotting detection system. The zeta chain was shown to be synthesized by the patient's T and natural killer cells. Northern blot analysis revealed normal levels of normal-size TCR beta and CD3 gamma, delta gene-specific mRNAs and decreased levels of TCR alpha mARN; CD3 epsilon gene transcripts were of abnormal size and present in lower than normal amounts. These findings suggest that this defect in T cell receptor-CD3 expression involves a mutation in the CD3 epsilon gene leading to the synthesis of an abnormal and unstable CD3 epsilon subunit.
Collapse
MESH Headings
- Antigens, CD/immunology
- Antigens, CD/metabolism
- Antigens, Differentiation, T-Lymphocyte/genetics
- Antigens, Differentiation, T-Lymphocyte/metabolism
- Antigens, Surface/metabolism
- Blotting, Northern
- Blotting, Western
- CD3 Complex
- Cell Membrane/metabolism
- Child, Preschool
- Electrophoresis, Gel, Two-Dimensional
- Electrophoresis, Polyacrylamide Gel
- Flow Cytometry
- Humans
- Immunologic Deficiency Syndromes/immunology
- Male
- Precipitin Tests
- RNA/metabolism
- Receptors, Antigen, T-Cell/genetics
- Receptors, Antigen, T-Cell/metabolism
- T-Lymphocytes/immunology
- T-Lymphocytes/metabolism
Collapse
Affiliation(s)
- G Thoenes
- Institut National de la Santé de la Recherche Medicale U 132, Hôpital Necker des Enfants Malades, Paris, France
| | | | | | | | | | | |
Collapse
|
46
|
Thoenes G, Soudais C, le Deist F, Griscelli C, Fischer A, Lisowska-Grospierre B. Structural analysis of low TCR-CD3 complex expression in T cells of an immunodeficient patient. J Biol Chem 1992. [DOI: 10.1016/s0021-9258(18)48521-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|